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Abstract
Chemotherapy Disrupts Bone Marrow Stromal Cell Function
Suzanne Davis Clutter
Advisor: Laura F. Gibson, Ph.D. Associate Professor Department of Pediatrics
A variety of bone marrow microenvironment derived signals influence steady state
hematopoiesis as well as hematopoietic recovery following bone marrow transplantation. Bone
marrow stromal cells found in this unique anatomical niche influence hematopoiesis, in part,
through production of soluble cytokines and chemokines. Developmental signals are also
initiated by physical interaction of hematopoietic progenitor cells with stromal cells which are
mediated by binding of their integrins to receptors on the stromal cell surface. Finally, the
extracellular matrix, including may components produced by stromal cells, provides structure as
well as a scaffold on which hematopoietic growth factors can be concentrated and stabilized in
the marrow. Efficient hematopoietic recovery following transplantation of stem or immature
progenitor cells requires sustained function of these components of the bone marrow during dose
escalated chemotherapy.
In the current study we investigated the effects of the chemotherapeutic agent etoposide
(VP-16) on bone marrow stromal cell function. We have previously demonstrated that stromal
cells chronically exposed to VP-16 display diminished extra-cellular levels of SDF-1 resulting in
disrupted support of pro-B cell chemotaxis. We have also determined that bone marrow stromal
cell MMP-2 protein is diminished following exposure to VP-16. Regulation of MMP-2 is
required for release of SDF-1 from stromal cell surfaces and ultimately required for optimal
support of chemotaxis. Additionally, VP-16 treatment results in alterations of pathways that
regulate protein translation, consistent with diminished translation of MMP-2 protein in treated
stromal cells. We also determined that following acute VP-16 exposure, MMP-2 activation was
transiently increased. Increased MMP-2 activity resulted in activation of TGF-β, which resulted
in diminished stromal cell support of pro-B cell adhesion and survival. Collectively, these data
contribute to our understanding of the global impact of chemotherapy on the bone marrow
microenvironment.
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CHAPTER I

INTRODUCTION AND REVIEW OF LITERATURE
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I. Hematopoiesis

Prenatal Hematopoiesis
Hematopoiesis, defined as the development of blood cells, initiates in the embryo and
development is characterized by migration of immature immune cells from one supportive niche
to the next (1).

The first sites of hematopoiesis in the developing embryo of both human and

mouse are the extra-embryonic yolk sac and the intraembryonic aorta-gonads-mesonephros
(AGM) region.

The extra-embryonic yolk sac is the site of blood island formation which is

where hematopoiesis originates. In mice, primitive hematopoiesis occurs in the blood islands of
the yolk sac at embryonic day 7.5 and in humans this process begins at embryonic day 15 and
continues for 6 weeks (2). In the yolk sac the only blood lineage cells which develop are
nucleated erythrocytes containing fetal hemoglobin and macrophages (3), therefore the yolk sac
is referred to as a primitive hematopoietic organ.
The AGM is the site of definitive hematopoiesis, with the process initiating in mice at
embryonic day 10.5 and in humans at embryonic day 30. It is in the AGM that development of
the first hematopoietic stem cell occurs (4;5).

Because all hematopoietic cell types can

differentiate from this pluripotent stem cell, the AGM is considered the site of initiating
definitive hematopoiesis.
Hematopoiesis shifts to the fetal liver at embryonic day 12.5 in mice and at
approximately 6 weeks in humans. The fetal liver is the site where constitution of the immune
system occurs and hematopoiesis primarily resides during embryogenesis (6). Embryonic HSC
migration to the fetal liver is regulated by integrin and chemokine expression. β1 integrin
expression is required for HSC colonization of fetal liver (7) and α4 is necessary for fetal T-cell
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development (8). In addition, deletion of the chemokine stromal cell derived factor-1 (SDF1/CXCL12) or its receptor CXCR4 blocks fetal liver B-cell hematopoiesis (9-11). The fetal liver
provides a microenvironment in which expansive proliferation of HSCs occurs (6;12).

In

humans hematopoiesis shifts during the second and third trimesters of gestation to the bone
marrow and thymus (13).

Postnatal Hematopoiesis
The primary site of postnatal hematopoiesis is the bone marrow. Blood cells are short
lived and therefore need to be continuously replenished throughout life. In addition, following
infection or blood loss, production of all blood cell types is essential.

The bone marrow

microenvironment provides all of the necessary requirements for hematopoiesis including growth
factors and adhesive interactions for blood cell development, which originates from the HSC.
Specific components of the microenvironment are described in more detail in section II.
The existence of a HSC was first suggested in 1909 by Alexander Maximow (14), with
more convincing evidence for a HSC provided in 1960. At that time, Till and McCulloch
transplanted bone marrow cells into irradiated mice and observed colony forming units in the
spleen (15). However, the term hematopoietic stem cell wasn’t coined until 1962 by Goodman
and Hodgson (16). The phenotype of human HSCs is CD34+, Lineage-, Sca-1+, c-kit+. These
pluripotent cells are found primarily adherent to osteoblasts in the “HSC niche” (17;18) as a noncycling population (19). Plasticity of HSC allows the differentiation into immune cells of the
lymphoid and myeloid lineages, including B-cells, T-cells, neutrophils, basophils, dendritic cells,
mast cells, macrophages, eosinophils, erythrocytes, and platelets, while maintaining the potential
to self-renew (Figure 1). Differentiation into lineage specific cells is regulated by stimulatory
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and inhibitory cytokines, and thymic or bone marrow stromal cells.

In a healthy human,

following maturation, lineage specific hematopoietic cells exit the bone marrow into the
peripheral blood as functional mature cells.
Steady-state hematopoiesis requires a balance of proliferation, differentiation, and
survival. Numerous factors regulate hematopoiesis, with pronounced redundancy. For example,
as many as seven different growth factors can stimulate the proliferation of megakaryocytes
colonies in culture (20). IL-3 can differentially regulate stem cells, erythrocytes, macrophages,
eosinophils, megakaryocytes, mast cells, and B-lymphocyte precursors (20;21).

Like other

necessary biological functions, redundancy within the system underscores the importance of
balanced, sustained hematopoiesis.
In contrast to evidence of redundancy, knockout mouse models have identified
hematopoietic defects that suggest several critical factors are both required and unique. Several
essential genes have been identified in primitive and definitive hematopoiesis including T-cell
acute leukemia-1/stem cell leukemia (TAL1/SCL) (22), T-cell leukemia LIM protein LMO2
(23), globin transcription factor-1 (GATA1) (24), fetal liver kinase-1 (FLK1) (25), the protein
tyrosine kinase, Tie2 (26), and creb-binding protein (CBP) (27). Mice in which these genes have
been knocked out die embryonically and exhibit a marked reduction in yolk sac hematopoiesis
and absence of fetal liver hematopoiesis. Many other genes including runt-related transcription
factor (AML/RUNX1) (28), GATA2 (29), c-MYB (30), c-kit (31) erythropoietin (EPO) (32) or
erythropoietin receptor (EPOR)(32;33) , janus kinase-2 (JAK2) (34), the transcription factor,
Pu.1 (35), Ikaros (36), Lim homeodomain (LHX) (37), nuclear receptor co-repressor (N-CoR)
(38), and RELA (39) are also imperative for definitive hematopoiesis. Mice lacking these genes
are also, for the most part, embryonic lethals. The exception is c-kit knockout mice which die at
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birth and Ikaros knockout mice which remain viable, but which have diminished HSC generation
and proliferation. Mice lacking the genes required for definitive hematopoiesis typically display
normal yolk sac hematopoiesis, but reduced or blocked fetal liver hematopoiesis. Mutation of
genes including β-1 integrin (7), α-4 integrin (8), and SDF-1 (9) or its receptor CXCR4 (10;11),
which regulate migration of hematopoietic cells and colonization of hematopoietic organs, also
result in embryonic lethality. Most of these genes listed which influence hematopoiesis encode
transcription factors, receptor tyrosine kinases, and adhesion molecules. Mice lacking the genes
described above, display ablation of hematopoiesis, however loss of additional proteins, not
discussed, are capable of disrupting lineage-specific hematopoiesis.
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Figure 1: Postnatal Hematopoiesis originates in the bone marrow and thymus from HSCs.

6

II. Bone Marrow Microenvironment

Anatomy of the Bone Marrow
The bone marrow microenvironment or hematopoietic microenvironment is defined as
the local network of stromal cells including fibroblasts, macrophages, endothelial cells and
adipocytes, accessory cells such as T-lymphocytes and monocytes, and their products including
extra-cellular matrix and cytokines. All of these factors are capable of influencing self-renewal,
proliferation and differentiation of hematopoietic stem and progenitor cells (40).

The

hematopoietic microenvironment was first described in 1966 from studies by Curry and Trenton
who called it the “hematopoietic inductive microenvironment” (HIM).

Their work suggested

the HIM is radioresistant, since hematopoiesis was supported in irradiated mice transplanted with
bone marrow cells (41). In addition to the bone marrow which supports more than 95% of adult
hematopoietic activity (40), the spleen can also act as a hematopoietic organ (42) under certain
conditions, such as stress. Till and McCulloch also observed that hematopoiesis was established
in the bone marrow and to a lesser extent in the spleen (15), providing further evidence for
specific microenvironments in which hematopoiesis is accomplished.
As defined above, the hematopoietic microenvironment is a network of cells and extracellular matrix which physically supports and influences the proliferation, differentiation, and
survival of hematopoietic cells (40). It has been suggested that hematopoiesis occurs in localized
microgeographical regions within the bone marrow and that the spatial distribution of lineage
specific hematopoiesis is not random (43). The specific hematopoietic “niche” will be discussed
in detail later, however, it is thought that in mammals hematopoiesis occurs in the extra-vascular
spaces between marrow sinuses (Figure 2) (44). Histological examinations of the bone marrow
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have identified the location of very immature hematopoietic cells concentrated within the
subendosteal areas, while more differentiated hematopoietic cells are located towards the center
of bone, away from the endosteum (45;46) . The sinus wall is lined with adventitial reticular cells
which aid in migration of mature blood cells from the marrow to the circulation (47). Reticular
cells comprise the majority of non-hematopoietic bone marrow cells. Along with adventitial
reticular cells, the bone marrow microenvironment also contains fibroblastic reticular cells which
play a major role in regulation of hematopoiesis (40). Throughout this dissertation “bone marrow
stromal cells” or “stroma” specifically refer to the fibroblastic reticular cells described above.

Bone Marrow Stromal Cells
Bone marrow stromal cells were first identified in culture by the fibroblastic colony
forming unit assay (CFU-F) assay (48) and were demonstrated to be capable of supporting
hematopoiesis (49).

Stromal cells are adherent, clonogenic, non-phagocytic, and can be

isolated from the bone marrow of post-natal mammals (44;50). Stromal cells produce several
cytokines which are known to regulate hematopoiesis including granulocyte-macrophage colonystimulating factor (GM-CSF), interleukin-1 (IL-1), IL-3, IL-5, IL-6, IL-7, IL-11, IL-12, leukemia
inhibitory factor (LIF), fibroblast growth factor (FGF), stem cell factor (SCF), FLT-3 ligand, ckit, macrophage colony stimulating factor (M-CSF), insulin-like growth factor-1 (IGF-1) and
tumor necrosis factor-α (TNF-α) (51-56).

Stromal cells also produce interferon-γ (INF-γ),

transforming growth factor-β (TGF-β), and macrophage inflammatory protein-1α (MIP-1α)
which serve as negative regulators of hematopoiesis (53-55). Identification of granulocytestimulating factor (G-CSF), IL-3, and IL-4 in murine and human stromal cell lines has not been
repeatedly detected (51;53;54).
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In addition to growth factors, bone marrow stromal cells also express adhesion molecules
and receptors responsible for physical contact with hematopoietic cells which are imperative for
regulation of hematopoiesis.

Stroma express the extra-cellular matrix proteins including

collagen I, III, IV, V, VI, fibronectin, vitronectin, laminin, thrombospondin, hemonectin, and
tenascin. Stromal cells also produce proteoglycans such as chondroitin sulfate, heparin sulfate,
CD44, and hyaluronate and cellular adhesion molecules (CAMs) including intracellular adhesion
molecule-1 (ICAM-1/CD54), N-CAM (CD56), vascular cell adhesion molecule-1 (VCAM1/CD106), leukocyte functional antigen-3 (LFA-3/CD58), αvβ3, and Thy-1 (CD90) (57-64). A
complete list of proteins expressed by stromal cells have been elucidated by micro-array (52),
however, their specific contribution to hematopoiesis, in many cases has yet to be determined.
Work described in Chapters 2 and 3 will specifically address the role of matrix
metalloproteinase-2 (MMP-2) in stromal cell support of hematopoiesis.
Bone marrow stromal cells were first demonstrated as capable of supporting
hematopoietic cells by Dexter, Whitlock, and Witte (65;66) utilizing long-term marrow cultures
(LTMCs). While stromal cells also support myelopoiesis (67-69), further discussion will focus
specifically on stromal cell support of B-lymphopoiesis.

Stromal Cell Support of B-lymphopoiesis
Development of B-cells occurs within the bone marrow microenvironment and requires a
series of differentiation steps which involve rearrangement of immunoglobulin variable region
gene segments. Upon successful rearrangement of a both a heavy and light chain variable
region, a highly regulated process involving the enzymes terminal deoxynucleotidyl transferase
(Tdt) and recombinase-activating enzymes 1 and 2 (Rag1 and Rag2), B-cells produce and
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express mature IgM. Once maturation is complete, B-cells enter the periphery and provide
immune protection through production of antibodies, presentation of antigen, or co-stimulation
of T-cells. In addition, a population of mature B-cells, termed plasma memory cells, reside in
the bone marrow providing long-term immunological memory (70). Genetic disorders such as
X-linked agammaglobulinemia (XLA) or Bruton’s disease, resulting in absence or very low
number of B-cells, renders individuals susceptible to bacterial infection from lack of circulating
antibody (71). Conversely, multiple myeloma, a disease characterized by excessive numbers of
abnormal plasma cells in the bone marrow, renders individuals susceptible to bacterial infection
due to lack of functional antibody production (72). These diseases which result in the absence of
B-cell homeostasis highlight the importance of regulation of B-cell function and development
throughout life.
Immature B cells, termed pre-pro-B, pro-B, and pre-B cells, which have not yet
successfully rearranged their variable regions, are dependent on direct bone marrow stromal cell
contact. In addition, cytokines produced by stromal cells are also required for pro- and pre-B
cell development (73;74).

IL-7, produced by bone marrow stromal cells, stimulates the

proliferation of immature B-cells (74;75). Along with pro- and pre-B cells, thymocytes, T-cells,
and NK cells also express IL-7 receptor (IL-7R) and proliferate in response to IL-7 (76;77).
Grabstein and Sudo have demonstrated that mice injected with anti-IL-7 or anti-IL-7R display
severely diminished numbers of pre-B cells (78;79), and IL-7 knockout mice demonstrate
blocked bone marrow B-lymphopoiesis at the transition from pro-B to pre-B cell stages (80).
However, Dittel has demonstrated that IL-7 alone is not sufficient for B-lymphopoiesis and
additional stromal cell factors are required for successful lymphopoiesis (81).
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IGF-1 is an essential growth factor for normal development and this is demonstrated by
observations that IGF-1 knockout mice exhibit postnatal lethality within the first 24 hours
following birth and display severe intrauterine growth retardation (82). IGF-1 is secreted by bone
marrow stromal cells and while IL-7 is the primary B-cell proliferative cytokine, IGF-1 enhances
the proliferation of IL-7 dependent pro-B cells (83). Injection of mice with recombinant IGF-1
significantly enhances the total number of bone marrow B lineage cells (84). Another factor
constitutively produced by stromal cells, stem cell factor (SCF), also enhances pro-B cell
proliferative response to IL-7 (85). SCF does not appear to be an absolute requirement for B-cell
development because mice that lack the SCF receptor, c-kit, display normal B-lymphopoiesis
(86). While IGF-1 and SCF are not essential for B-lymphopoiesis, their role in the enhanced
response to IL-7 demonstrates their importance in stromal cell support of B-lymphopoiesis.
Stromal cells produce FLT-3L, an essential factor for B-cell development (87;88).
Similar to IGF-1 and SCF, FLT3L stimulates the growth of pre-pro-B cells synergistically with
IL-7 (89). FLT3-deficient mice display diminished numbers, by two-fold, of pre-pro-B cells and
pro-B cells, while the numbers of pre-B cells, and mature B cells remain normal (90). Similarly,
FLT3L-deficient mice display dramatically diminished numbers of pre-pro-B, slightly reduced
numbers of pro-B and pre-B, and normal numbers of mature B-cells (87;88).
Along with cytokines, stromal cells also express adhesion molecules which participate in
regulation of B-lymphopoiesis.

Early studies by Witte utilizing LTMC assays described

lymphocytes as, “attached to, or pressed beneath large stromal cells” (91). Chelation of divalent
cations inhibited the attachment of lymphocytes to stroma, while adherence was re-established
following removal of chelating agents. These observations suggest that lymphocyte precursors
express adhesion molecules which selectively recognize ligands on stromal cells (91). One
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particular CAM, VCAM-1, constitutively expressed by stromal cells, has proven functionally
important in LTMC. Simmons et al. discovered that VLA-4/ VCAM-1 mediate the binding of
immature progenitors to stroma in LTMC (92). Addition of either anti-VCAM-1 antibody or
antibody specific for its receptor, VLA-4, to established Whitlock-Witte cultures results in rapid
detachment of lymphocytes from the adherent stromal cell layer (93).

Additionally, more

immature B cells express higher levels of VLA-4, consistent with increased binding to stromal
cells (94). While there is strong evidence for VLA-4/VCAM-1 interaction in B-lymphopoiesis,
other adhesion molecules are also involved in B-cell adherence to stroma. Antibody specific to
CD44, expressed on both stromal cells and pro-B cells, inhibits murine B-lymphopoiesis in vitro
(95). Adhesion molecules serve many functions within the bone marrow microenvironment
including retention of immature hematopoietic cells within the marrow, and providing growth
and survival signals. It is also thought that adhesion of hematopoietic cells to stromal cells and
extra-cellular matrix directs cells to microenvironments located within the bone marrow, termed
“niches” (96).
SDF-1 is a member of the CXC group of chemokines initially identified as a stromal cell
soluble factor which stimulates pre-B cells (97). SDF-1 is constitutively expressed in many
organs including brain, heart, lung, liver, thymus, spleen and kidney (97) and is essential for
perinatal viability, B-lymphopoiesis, bone marrow myelopoiesis, and cardiac ventricular septal
formation (98). CXCR4 was the only identified receptor for SDF-1 for many years and also
serves as a co-receptor for HIV entry into T-cells (10). However, recently another SDF-1
receptor, the chemokine orphan receptor-1 or RDC1/CXCR7, has been identified (99).
RDC1/CXCR7 is present on T-cells and promotes SDF-1 directed chemotaxis which is blocked
using an antibody specific for RDC1/CXCR7 (99). Recent evidence suggests inhibition of SDF-1
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or CXCR4 with specific neutralizing antibodies in LTMC inhibits the proliferation and cell cycle
of immature hematopoietic cells (100). Along with its contribution to B-lymphopoiesis, SDF-1
also plays a major role in homing and mobilization of B-cells and therefore will be discussed in
more detail later.
Stromal cells also express inhibitors of B-lymphopoiesis including IL-1, IL-4, TGF-β,
INF-γ, and estrogenic steroids. While it has been reported that IL-4 and IL-1β up-regulate
VCAM-1 expression (101), much evidence suggests both cytokines negatively regulate the
proliferation and differentiation of immature B-cells (102-104).

Murine S17 stromal cells

exposed to either IL-1α or IL-4 do not support the development of pre-B cells (105). Negative
regulation of B-lymphopoiesis may be influenced, in part, by IL-4 and IL-1α stimulation of
stromal cells to up-regulation expression of cytokines that support myelopoiesis including, GMCSF and G-CSF (106;107).
TGF-β is another stromal cell product which negatively regulates support of Blymphopoiesis (108).

It was originally described for its ability to promote anchorage

independent growth of fibroblasts (109) and displays both stimulatory and inhibitory activities
depending on the target cell type and presence of other growth factors (110;111). TGF-β inhibits
lymphocyte proliferation, B-cell antibody secretion, and NK cell function (112;113).
Additionally TGF-β inhibits the differentiation of pre-B cells to mature, functional B-cells (108).
Another negative regulator of hematopoiesis, TNF-α, acts similarly to IL-1α by blocking the
growth of immature B-cells (55) and inducing the release of myeloid growth factors (114).
Stromal cell regulation of B-lymphopoiesis is a combination of pathways involving
chemokines, cytokines, and adhesion molecules which function in cooperation to inhibit or
stimulate B-lymphopoiesis. As mentioned previously, SCF and IGF-1 cooperate with IL-7 to
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stimulate proliferation of pro-B cells. SDF-1 increases the affinity of VLA-4, up-regulating
extravasion of cells into the bone marrow (115). In addition, molecules such as c-kit can provide
dual functions of proliferation and adhesion which both participate in regulation of Blymphopoiesis (116).

Regulation of B-lymphopoiesis is an essential stromal cell function;

however, bone marrow stromal cells have other regulatory functions within the bone marrow
microenvironment.

Stromal Cell Plasticity
In 1974 during work establishing the CFU-F assay, Friedenstein et al. first proposed that
bone marrow contained a precursor cell for multiple mesenchymal lineages (117). Since that
time it has been well established that stromal cells, also called mesenchymal stem cells, are
capable of differentiating into bone (118;119), adipose (120), cartilage (121), smooth muscle
(122), and neurons (123).
Incubation of stromal cells with bone morphogenic proteins (BMP) induces rapid
differentiation towards the osteoblast lineage both in vivo and in vitro (124;125) and cells
maintain a phenotype consisting of cuboidal morphology, express alkaline phosphatase and
osteocalcin, and form mineralization nodules (126). While osteoblasts differentiate from bone
marrow stromal cells, they also aid in regulation of hematopoiesis. Osteoblasts provide structure
to the bone marrow microenvironment and influence the differentiation of hematopoietic cells
through the secretion of several cytokines which regulate hematopoiesis including G-CSF, GMCSF, IL-6, IL-1β, TGF-β, and TNF-α (127). In addition to osteoblasts, stromal cells can also
differentiate into chondrocytes (121) which produce collagen type I, II, and IX (128). Following
extensive culture with corticosteroids, stromal cells can give rise to adipocytes (120). Myoblasts
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expressing α-smooth muscle actin, metavinculin, calponin, and myosin heavy chain can be
generated by stromal cells cultured in the presence of 5-azacytidine and basic fibroblast growth
factor (bFGF) (122) or amphotericin B (129).

Finally, differentiation of neural cells was

demonstrated following culture of stromal cells with bFGF, β-mercaptoethanol, dimethyl
sulfoxide (DMSO), and butylated hydroxyanisole (123;130). The mechanism by which stromal
cells differentiate to neuronal cells is not currently understood, but phenotypic changes occur
very rapidly, after 5 hours in culture.

Additionally, stromal cells injected into the lateral

ventricle of mice migrate to neuron-rich areas and differentiate into neurons (131). As stated
above, bone marrow stromal cells demonstrate a high degree of plasticity and therefore may be
potentially useful in the clinical setting of regenerative medicine.
Bone marrow stromal cells also possess many attributes which makes them likely
candidates for transplantation. Transplantation with xenogenic, allogeneic, or gene-transduced
stromal cells does not result in rejection (132-134). The mechanism for this could arise from the
fact that stromal cells are not well recognized by alloreactive T-cells (132) because they do not
express major histocompatibility complex type-II (MHC-II) or co-stimulatory molecules (135).
Additionally, stromal cells are capable of engrafting to numerous organs when transplanted
(136). Another advantage of utilizing stromal cells for transplantation is that they are easy to
obtain in large numbers and can be readily expanded in culture. In addition to the fact that they
display plasticity, stromal cells can easily be transduced with vectors or can function as retroviral
producer cells and therefore are useful candidates for gene therapy (137-140).
Many studies have already demonstrated the potential clinical utility stromal cells
possess.

Transplantation of stromal cells into articular spaces completely repairs cartilage

defects (122). Transplantation of stromal cells in conjunction with hematopoietic cells enhances
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the engraftment potential of the hematopoietic cells (141-144;144). Transplanted bone marrow
stromal cells are capable of integrating into the functional components of the bone marrow
microenvironment and maintaining human hematopoiesis (145). Finally, allogeneic stromal cells
transplanted into children with osteogenesis imperfecta (OI) engraft, and differentiate into,
osteoblasts (146). Following stromal cell transplantation, the number of osteoblasts increased,
new lamellar bone formation was detected, an increase in total body mineral content was
detected, fewer fractures occurred , and increased growth velocity was observed (146).

Additional Cell Types in the Bone Marrow
In addition to stromal cells and hematopoietic cells, the bone marrow microenvironment
also contains macrophages and microvascular endothelial cells. Macrophages are derived from
the hematopoietic stem cells; however, in the bone marrow, macrophages produce many
hematopoietic regulatory factors rendering them part of the supportive system. Macrophages
produce GM-CSF, G-CSF, M-CSF, IL-6, IL-1, TNF-α, and TGF-β (40). Within the bone
marrow two populations of macrophages exist; the central macrophages and the peri-sinusioidal
macrophages. The central macrophages aid in the differentiation of erythroid progenitors and
comprise the erythroblastic island while the peri-sinusoidal macrophages destroy defective
erythrocytes by penetrating the endothelial walls (147).
Microvascular endothelial cells also contribute to bone marrow hematopoiesis. Bone
marrow derived endothelial cells constitutively express IL-6, G-CSF, GM-CSF, M-CSF, SCF,
and fetal liver kinase-2 (Flk-2). In addition, endothelial cells also express adhesion molecules
including VCAM-1, ICAM-1, E-selectin, and P-selectin. Egress of mature hematopoietic cells
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into the periphery requires extravasion through the endothelial cell layer lining the vasculature in
the marrow (148).

Hematopoietic Stem Cell Niche
As described previously, hematopoiesis requires a specific microenvironment or
“supportive niche” within the marrow microenvironment. HSCs require protection from stress,
adhesion to niche cells, and a hypoxic environment. Therefore, the HSC niche must meet all of
these requirements (149). While molecules involved in the maintenance of HSC quiescence
have been identified, including c-kit (150), identity of the microgeographical region in which
HSCs reside was only recently identified. In 2003 the HSC supportive niche was identified by
Calvi et al, and Zhang et al. and implicated osteoblasts as crucial regulator cells in this
environment (18;151). Osteoblasts support the adhesion and quiescence of HSCs, therefore
providing essential requirements for HSC populations (18). It has been reported that in contrast
to quiescence, a unique population of HSCs in the bone marrow undergoes proliferation. Calvi et
al. have demonstrated that proliferating osteoblast populations increase and decrease in
correlation with the number of proliferating HSCs. This observation provides evidence for
another level of osteoblast regulation of HSCs (152). Further evidence for osteoblast regulation
of HSC maintenance comes from mice with osteoblast deficiency. Transgenic mice expressing
the herpes virus thymidine kinase gene under control of the collagen α1 promoter display
severely suppressed hematopoiesis (153).

B-cell Niche
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Comparable to HSCs, B-cells are also regulated in specialized microenvironments or
niches (Figure 2). In 2004 Tokoyoda et al. utilized mice expressing GFP in the SDF-1 locus to
identify specific niches in which B-cell development occurs. Common lymphoid progenitors
and fully differentiated plasma cells require contact with stromal cells expressing SDF-1, while
IL-7 dependant pro- and pre-B-cells are found in a different location within the bone marrow,
adjacent to stromal cells expressing IL-7 and SDF-1.

This work demonstrates that B-cell

development occurs within specialized niches and development proceeds as cells migrate
between functionally distinct supportive niches (154).

Collectively, the diverse cell types,

signals, and anatomically unique niches reflect the complexity of the bone marrow
microenvironment. Further regulatory cues are provided by the extra-cellular matrix in this same
site, described in the following section.
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III. Extra-cellular matrix

Role of ECM in Hematopoiesis
Stromal cells produce and secrete extra-cellular matrix (ECM) proteins that form the
highly organized ECM of the bone marrow microenvironment. The major components of the
ECM include collagen types I, III, IV, V, and VI, fibronectin, vitronectin, laminin,
thrombospondin, and proteoglycans (155;156). These proteins not only provide a structural
support within the bone marrow, but also regulate hematopoiesis by binding, stabilizing, and
presenting cytokines and growth factors to developing hematopoietic cells. These roles allow the
ECM to directly participate in the control of cell proliferation and differentiation as well as the
survival of hematopoietic cells (157).
It is known that cytokines not only interact with their cognate receptors, but also function
in cooperation with ECM proteins. Cytokines influence the expression and turnover of specific
ECM molecules and conversely, ECM proteins mediate the synthesis of cytokines (158;159). In
addition, ECM proteins serve as co-receptors for cytokines and many cell surface receptors are
utilized in the clustering of cytokine receptors which influence signal transduction (160;161).
Finally, some cytokines can directly bind to ECM proteins which serve to localize and stabilize
cytokines for later release (162).
TGF-β, as described in section II, is a negative regulator of B-cell hematopoiesis and
provides an example of the role bone marrow ECM plays in mediating cytokine activity. TGF-β
is a member of the TGF-β super-family which includes not only TGF-βs, but also the BMPs.
These molecules are involved in regulation of diverse cellular processes and gene knockout
studies have confirmed their importance. TGF-β-1-/- mice develop a severe autoimmune reaction

20

two weeks after birth, confirming TGF-β’s importance in immune regulation (163;164). TGF-β
activity is regulated exclusively at the post-translational level by the presence of inhibitory
binding proteins (165). TGF-β is synthesized in an inactive form, “pre-pro-TGF-β”. Upon
secretion, cleavage of the pro-peptide of TGF-β occurs. However, in order to become active,
TGF-β inhibitory proteins must be proteolytically cleaved or sequestered away from the active
form of TGF-β (165;166). Inactive TGF-β, is bound to both latency associated protein (LAP)
and latent TGF-β binding proteins (LTBPs). Serine proteases, including MMP-2, are capable of
cleaving LAP and LTBPs from TGF-β (165) and data presented in Chapter 3 suggests MMP-2
specifically activates bone marrow stromal cell TGF-β through cleavage of LAP and LTBP
(167).
Upon activation, TGF-β can bind to the ECM proteins betaglycan and endoglin or the
TGF-β receptor. Binding of TGF-β to betaglycan or endoglin does not result in transmission of a
cellular signal, however it does serve to present TGF-β to its receptor (159).

Active TGF-β-

bound betaglycan can be shed from the cellular surface. The proteoglycan-bound TGF-β acts as
a receptor antagonist by inhibiting TGF-β–receptor binding (168). Regulation of TGF-β activity
provides one example in which ECM influences cytokine activity and availability.
While all members of ECM contribute to hematopoiesis, proteoglycans provide the
majority of ECM-cytokine/growth factor interaction provided within the bone marrow
microenvironment. Specific emphasis on one proteoglycan, heparin sulfate, and its direct role in
SDF-1 regulation is the primary focus of this section. Both human (169) and murine (155)
marrow stromal cells express heparan sulfate proteoglycan on their surface, along with marrow
derived stromal cells lines (170;171).

Many proteins associate with stroma through direct

interaction with heparan sulfated proteoglycans present on stromal cell surfaces (58;59). Work
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by Gallagher and colleagues comparing adherent cells from bone marrow cultures and utilizing
W/Wv mice indicated that bone marrow stromal cells are the primary source of sulfated GAGs in
the marrow (155).

Heparan-Sulfated Proteoglycans
Proteoglycans are a heterogeneous group of macromolecules characterized by at least one
glycosaminoglycan (GAG) chain attached to a core protein. GAG chains are unbranched, acidic
heteropolysaccharides consisting of repeating disaccharides. There are three types of sulfated
GAGS: chondroitin or dermatan sulfate, heparan sulfate, and keratan sulfate. Heparan sulfate is
present in most culture cell extracts and is present as both an integral membrane glycoprotein
and as a surface-associated component bound to membrane receptors (172;173). The
polysaccharide backbone of heparin sulfate is comprised of N-acetyl glucosamine and glucuronic
acid residues which are modified by a series of reactions. During synthesis of the heparan
sulfate chain, the modification steps which generate the final structure are often incomplete
which results in structural heterogeneity leading to the potential for an enormous variety of
molecular interactions (174;175). In addition, heparan sulfate chains can form dimers, (176)
further adding to its diversity in regulating cell/ECM interactions. Direct evidence also exists for
GAGs in stimulation of hematopoiesis. Addition of xylosides, which synthesize sulfated GAGs
(177), to long-term in-vitro bone marrow cultures significantly increases hematopoietic support
(178).
Bone marrow stromal cell heparan sulfated proteoglycans bind and present many
chemokines on their surface including IL-8, MIP-1β, growth-related activity-α (GRO-α) and
SDF-1 (179-182). SDF-1, as described in Section II, is an important factor in hematopoietic
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regulation. Along with in vitro data, in vivo data also suggests SDF-1 is sequestered on heparan
sulfated proteoglycans (183;184). Lys24 and Lys27 mediate the high affinity binding of SDF-1
(Kd of 30nM) to heparan sulfate GAGs (162). Serine substitution of these amino acids results in
inability of SDF-1 to bind heparan sulfate (185). Also involved in, but not required for, this
interaction are Lys1, Arg41, and Lys43 residues of SDF-1 (162). Heparan sulfated proteoglycans
immobilize and enhance the local concentration of SDF-1 which facilitates its presentation to
CXCR4 (186;187). Inactivation of the heparan sulfate binding sites does not interfere with SDF1’s ability to bind CXCR4 and heparan sulfate bound SDF-1 is capable of binding CXCR4 (185).
Regulation of SDF-1’s activity can occur by proteolytic degradation. The high affinity
binding of SDF-1 to GAGs of heparan sulfate prevent dipeptidyl peptidase IV (DPP IV)-induced
cleavage of the chemokine which results in instability (188-190).

In addition to DPP IV,

MMPs, including MMP-2, are capable of cleaving SDF-1 (191). MMP-2 cleaves the first 4
amino acids of SDF-1 which renders the protein unstable and unable to support chemotaxis of
CXCR4+ cells. Following the initial cleavage, SDF-1 undergoes auto-degradation. Proteolytic
cleavage is the only post-translational regulatory mechanism described for SDF-1 and data
presented in chapter II of this dissertation describes a novel role for MMP-2 involvement in
regulation of SDF-1.

Matrix Metalloproteinases
MMPs are endopeptidases that were first recognized for their ability to degrade proteins
of the ECM (192). MMPs are involved in regulation of embryonic morphogenesis, angiogenesis,
growth, wound healing, and also contribute to pathological processes including arthritis, tumor
invasion and metastasis, and the progression of hematopoietic neoplasms (193).
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Recently,

evidence has suggested that MMPs are critical for cell/ECM interactions and aid in regulation of
cellular differentiation, migration, apoptosis, and cytokine activity.
In 1962 Gross and Lapiere discovered that MMPs were the protein responsible for
removing the tail during tadpole metamorphosis (194). Since then, there have been 25 MMPs
isolated from vertebrates and 22 human homologues (192). These proteins are widely distributed
among the animal kingdom and have been found in sea urchins (195), Drosophila (196),
Caenorhabditis elegans (197), and green algae (192;198). MMPs are divided into families based
on their structure, substrate specificity, and localization within the cell. The collagenase family
contains MMP-1, -8, and -13 and their substrates include almost all members of the ECM. The
gelatinases A and B, MMP 2 and 9 respectively, are another MMP family that cleaves gelatin
and most collagens.
MMP family.

Stomelysins 1 and 2, also known as MMP-3 and 10, comprise another

MMP-3 is commonly seen in rheumatoid arthritis and inflammatory bowel

diseases. A more heterogeneous population of MMPs known as the classical MMPs, include
MMP-12, -19, and -20.

This family is recognized for their specific activity in localized

environments an example being enamalysin, MMP-20, which is only present in epithelial cells in
the oral cavity. The last family of MMPs is the membrane bound members, also designated as
membrane type-MMPs (MT-MMPs), and includes MT-MMP-1,-2, -3, -4, and MMP-11. The
MT-MMPs are thought to aid in the localization and activation of secreted MMPs.
The structure of MMP molecules exhibit a signal sequence, termed the pre-domain,
consisting of approximately 20 amino acids, a pro domain of approximately 80amino acids, a
catalytic domain of roughly 170 residues, a 10-70 residue proline rich linker sequence and a 195
amino acid C-terminal hemopexin-like domain. MT-MMPs also contain a 75-100 residue transmembrane and cytoplasmic fragment (199).

All MMPs are secreted as catalytically latent
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enzymes which subsequently become activated in the peri-cellular environment. The catalytic
domain contains an essential zinc molecule which dictates the proteolytic activity of MMPs. In
latent form, an unpaired cysteine in the pro-domain is bound to the catalytic zinc molecule. In
order to become activated, the pro-domain must be removed from the N-terminus of the
molecule which interrupts the cysteine-zinc molecular interaction. Once free from the prodomain, the catalytic zinc can interact with substrates. Substrate specificity is dictated, in part,
through active site structural requirements as well as binding sites along the MMP molecule. For
example, MMP-2 and 9 contain hemopoiexin domains which dictate the substrate specificity of
the molecule. As indicated earlier, SDF-1 is a MMP target with specific relevance to the studies
included in this dissertation.

Inhibitors of Matrix Metalloproteinases
MMP activity is highly regulated. One level of regulation is accomplished by the extracellular inhibitors known as tissue inhibitor of matrix metalloproteinases (TIMPs). The four
human TIMPs, TIMP-1, -2, -3, and -4, are capable of binding to all MMPs, but these complexes
display different inhibition properties. TIMPs are 20-29 KD secreted proteins that reversibly
inhibit MMP activity (200).

TIMP molecules are comprised of 2 domains: an N-terminal

domain consisting of 125 amino acids and a C-terminal domain of 65 amino acids. Three
disulfide bonds in each domain stabilize the molecule (200). TIMPs inhibit MMPs through the
action of their first five amino acids, Cys-1 through Pro-5. These amino acids form a wedge
shape that inserts into the catalytic center of the MMP molecule allowing for chelation of the
catalytic Zn molecule. Specifically, the amino N and carboxyl O of Cys1 perform the chelation
effect (201). The N-terminal domain contains the catalytic portion and is more conserved among
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TIMP isoforms. The C-terminal domain is more variable between TIMPs and is the region
capable of binding to pro-MMPs (200;202). The interaction between TIMPs and pro-MMPs
provides a paradoxical role for TIMPs; TIMPS can aid in the activation of MMP molecules by
acting as a membrane-docking molecule. An example of this behavior occurs when the Nterminus of TIMP-2 binds to MTI-MMP-2. This allows the free C-terminus of TIMP-2 to bind
the hemopoiexin domain of secreted pro-MMP-2 (203). A second, uninhibited MT-MMP-2
cleaves the pro-domain of MMP-2 and consequently activates the MMP that is bound to TIMP-2
(204). This unorthodox role of TIMP-2 is proposed to localize MMP action near the cell surface
(203).

Low levels of TIMP-2 promote the activation of MMP-2 and high levels bind MT-

MMPs so activation cannot occur (202).
In addition to TIMPs, many chemical inhibitors have been designed to inhibit the activity
of MMPs both in vitro and in vivo. Chelation of the catalytic zinc molecule of MMPs allows for
reversible inhibition, therefore any substance capable of this action can inhibit MMP activity.
The most common synthetic inhibitors include o-phenanthroline, which chelates all divalent
cations and therefore does not offer specificity (205).

Hydroxamates are synthetic MMP

inhibitors also capable of chelation, but do so in a different manner. Hydroxamates include
batimastat (BB-94), and marimastat (BB-2516), which contain a collagen like backbone that
allows binding to MMP active site; they also contain a hydroxamate structure that chelates the
catalytic zinc (206). Antibiotic compounds are capable of producing hydroxamates and therefore
also possess MMP inhibitory activity. Tetracycline and doxycycline are shown to have IC50 for
MMPs both in vivo and in vitro (207). Hydroxamate-based synthetic inhibitors are considered to
be the most effective in inhibiting MMPs (208). Additionally, inhibitors have been designed to
act as pro-domains of MMP molecules which keep the enzyme in latent form. Macrocylic
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lactones, such as bryostatin-1 have recently been implicated for their role in MMP inhibition.
These inhibitors activate PKC through tight binding, but unlike other PKC activators, allow for a
rapid PKC down-regulation (209). Bryostatin does not affect the activity of MMPs, but results
in the absence of MMP-1, 3, 9, and 11 production (210).

Matrix Metalloproteinase-2
The bone marrow stromal cells used in our study predominately produce MMP-2. MMP2 was cloned and characterized in 1992 by Reponen (211). The amino acid sequence contains a
29-residue signal peptide, and 80-residue pro-peptide, and 553-residue catalytic and functional
domains. Murine and human MMP-2 share 96% sequence homology with all cysteine residues
conserved (211). MMP-2 is expressed in mouse lung, heart, kidney, and muscle tissue while
absent from liver, spleen, and brain. Mesenchymal cells from 10-15 day old embryo also show
intense staining of MMP-2 (211).

MMP-2 knockout mice do not have developmental or

reproductive defects; however, they display retarded growth (212).

Work by others has

demonstrated that MMP-2 knockout mice display an increased incidence of experimental
autoimmune encephalomyelitis (EAE) (213;213) and antibody induced asthma (214) as well as
disrupted corneal neovascularization (215). In addition, humans with a mutation in the MMP-2
gene (chromosome 16q12-21) display an arthritic syndrome described as multicentric osteolysis
or “vanishing bone syndrome” (216). Persons with this nonsense mutation have disrupted
hydrogen bond formation between the MMP-2 pro-domain and the catalytic Zn. No enzymatic
MMP-2 activity is detected and consequently they display carpal and tarsal resorption, crippling
arthritis, osteoporosis, and palmar and plantar subcutaneous nodules. This mutation is prevalent
among Saudi Arabian families (217).
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While many in vitro substrates for MMP-2 have been described, including all members of
basement membrane, recent work has demonstrated MMP-2 cleaves many proteins involved in
regulation of hematopoiesis. As described earlier, McQuibban has shown MMP-2 removes a
tetra-peptide from the N-terminus of SDF-1 resulting in a protein that is no longer functional
(191). Also discovered by McQuibban et al., MMP-2 can cleave another chemokine, monocyte
chemoattractant protein -3 (MCP-3) resulting in a protein no longer capable of supporting
chemotaxis (218).

Introduced earlier, MMP-2 cleaves TGF-β LAP and LTBPs (167).

Additionally, MMP-2 has been described by Fowlkes as capable of releasing IGF-1 from
inhibitory binding proteins resulting in an active IGF-1 molecule (219). Finally, MMP-2 has
been implicated in the cleavage of proteoglycan molecules. Zuo et al. have shown MMP-2 from
neurons degrades and inactivates chondroitin sulfate proteoglycans (220). Increasing evidence
implicates MMP-2 as a modulator of hematopoietic cytokine activity and defines a novel role for
MMP-2 in the regulation of hematopoiesis.
All MMPs, with the exception of MMP-2, which is constitutively expressed by most cell
types, are regulated at the transcriptional level (221).

Characteristics of MMP-2 mRNA

including a high degree of secondary structure and the presence of a 5’ tract of pyrimidines
(5’TOP) allow the protein to be controlled by translational regulatory mechanisms (222). The
specific pathways which are involved in translational regulation of MMP-2 expression in bone
marrow stromal cells are the focus of Chapter IV.
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IV. Hematopoietic Cell Trafficking

Bone Marrow Transplantation and Engraftment
In 1951 Lorenz et al. found that administration of hematopoietic cells into mice shortly
after receiving high dose γ-irradiation prevented their death (223). Survival of these mice was
the result of the colonization of the irradiated mouse by the injected hematopoietic cells (224). It
has now been established that bone marrow transplantation (BMT) is an accepted mode of
therapy for immunodeficiency disorders and aplastic anemia (225;226), hematologic
malignancies including non-Hodgkin’s lymphoma in relapse (227), acute myelogenous leukemia
(228), acute lymphocytic leukemia (229), and multiple myeloma (230). In addition, solid tumors
including ovarian, breast, and lung carcinoma have been successfully treated with BMT
(231;232).

A successful BMT is characterized by both numerical recovery of bone marrow

cellular elements and functional recovery of cellular interactions.

Specifically, immune

reconstitution is indicated by appearance of functional B-cells, thymic and extra-thymic T-cell
development, reconstitution of effector cells including cytotoxic T-cells and natural killer cells,
as well as efficient antigen presentation (233). Because complete reconstitution of the immune
system often takes at least one year, patients receiving a BMT are extremely susceptible to lifethreatening bacterial, viral and fungal infections (234).
Intravenous injection of bone marrow cells into recipients receiving a BMT “home” or
migrate to several organs, including the bone marrow. The bone marrow microenvironment is
the predominant site that supports hematopoietic reconstitution (235-237).

Although,

hematopoietic reconstitution is established exclusively within the bone marrow, the initial steps
in the process of homing are not specific to the bone marrow. Homing of transplanted cells is a

29

two-step process where cells must first be recognized by, and interact with, the bone marrow
endothelium where they diapedes into the bone marrow extravascular spaces. The second step is
the interaction of the stem and hematopoietic progenitors cells with bone marrow stromal cells
that support proliferation and maturation (238).
The adhesion molecules VCAM-1/VLA-4 are required for efficient engraftment.
Hematopoietic cells incubated with anti-VLA-4 antibody prior to infusion into mice display 50%
reduction in the ability to engraft to the bone marrow (239). In similar studies, a 54% reduction
in bone marrow engraftment was obtained when recipient mice were treated with anti-VCAM-1
antibody prior to transplantation (239).
The SDF-1/CXCR4 axis, described previously, also plays a role in the ability of cells to
engraft to the bone marrow microenvironment. Immature hematopoietic cells isolated from the
fetal liver of CXCR4-/- mice are unable to home to the bone marrow microenvironment,
indicating the role of CXCR4 in engraftment (240). In addition, the migration of HSCs isolated
from adult mice, is supported exclusively by SDF-1 as indicated by in vitro chemotaxis assays
(241).

Taken together, these results demonstrate essential roles for SDF-1 and CXCR4

interactions in HSC homing.

Mobilization
Terminally differentiated, mature hematopoietic cells egress from the bone marrow into
the periphery. The mechanism by which mature cells leave the marrow sinusoids and enter into
circulation is poorly understood. In addition to mature cells, mobilization of hematopoietic stem
and progenitor cells from the bone marrow into the periphery can be induced by cytokines such
as GM-CSF (242), G-CSF (243), IL-3 (244), IL-7 (244), SCF (245), chemokines such as IL-8
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(246), and MIP-1α (244), chemotherapy (247), and antibodies to adhesion molecules (248).
Mobilized hematopoietic cells are often used in place of bone marrow cells for transplantation
and have been established as capable of repopulating the hematopoietic compartment. Prior to
the discovery of mobilizing agents, patients receiving a BMT were infused with allogeneic or
syngenic bone marrow cells. Advantages of utilizing mobilized HSCs are that they lead to faster
recovery in transplanted recipients as compared to patients transfused with bone marrow cells
and the mobilized cells are easier to collect.

The faster engraftment is due to the increased

number of mobilized cells as compared to the number of cells that are able to be collected by
bone marrow aspiration for subsequent transplantation (249;250).
Evidence implicates fluctuations in SDF-1 levels provide the cue for cells to leave the
bone marrow and enter circulation. A rapid increase in SDF-1 protein is observed in circulation
of mice and primates treated with the mobilizing agent fucoidan (183), and patients exposed to
G-CSF (251). Petit and colleagues suggest diminished levels of bone marrow SDF-1 is due to its
degradation by proteases.

In accordance with elevated peripheral blood SDF-1, HSC

mobilization occurs with diminished levels of bone marrow SDF-1 (252).
Adhesion molecules are also implicated in mobilization of HSCs from the marrow. The
adhesion molecule expressed on stromal cells, VCAM-1, is proteolytically cleaved following
exposure to the mobilizing agent G-CSF (253). Consistent with its ability to inhibit engraftment,
administration of antibody specific to either VLA-4 or VCAM-1 results in mobilization of
immature hematopoietic cells (239).
While proteases have been implicated by Levesque’s group as the primary mechanism for
cytokine-induced mobilization of HSCs, elevated protease levels do not entirely account for this
phenomenon. Neutrophil elastase, cathepsin G, and MMP-9 knockout mice are able to mobilize
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hematopoietic cells in the presence of G-CSF (254). Very recently a novel mechanism for
fucoidan and G-CSF induced mobilization was elucidated by Frenette.

Mice lacking UDP-

galactose ceremide galactosyltransferase (Cgt), an enzyme necessary for myelin sheath
formation, were demonstrated to be unable to mobilize HSC or other immature hematopoietic
cells in the presence of fucoidan and G-SCF (255).

The sympathetic nervous system,

specifically the neurotransmitter norepinephrine (NE), was implicated as the responsible
mediator since dopamine β-hydroxylase (Dbh) deficient mice which lack NE are also unable to
mobilize HSCs. The authors also found that bone marrow SDF-1 levels remained elevated in
both Cgt-/- and Dbh-/- mice exposed to mobilizing agents while bone marrow SDF-1 levels were
diminished in wild-type mice exposed to the same mobilizing agents. While the mechanism for
trafficking of hematopoietic cells between the periphery and the extra-vascular spaces of the
bone marrow is still not completely understood, adhesion molecules, chemokines, proteases, and
neuro-transmitters may all impact on this process.

Bone Marrow Damage
To this point, regulation of hematopoiesis by a “healthy” bone marrow microenvironment
has been described. In contrast, our experimental model that was designed to determine how
chemotherapy disrupts the “normal function” of the bone marrow microenvironment. It has been
established that following high-dose cytotoxic therapy and/or radiation exposure, given prior to
transplantation, patient derived bone marrow stromal cells display functional deficits (256-258).
Studies by Galotta et al. found that BMT recipient CFU-F frequencies were reduced 60-90% and
did not recover for up to 12 years following transplant (259). Another study found that patients
who received a BMT with mobilized HSCs display diminished stromal function one year
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following the BMT (260).

Acute lymphoblastic leukemia (ALL) patients who received

chemotherapy prior to a BMT were found to have significantly reduced hematopoietic supportive
stroma, due partially to an increase in TGF-β levels (261). Both irradiated and chemotherapy
exposed mice display similar functional deficits in the ability of their stromal cells to support
hematopoiesis (258;262;263).
The mechanisms by which stromal cell support of hematopoietic cells is diminished
following chemotherapy exposure has yet to be determined. Studies performed in our laboratory
have determined that stromal cells exposed to chemotherapy display diminished VCAM-1
expression due to alterations in NF-κB transcription (264;265). Additionally, SDF-1 production
is diminished resulting in diminished support of pro-B cell chemotaxis in stromal cells exposed
to chemotherapy (266).

Consistent with diminished ability to support hematopoietic cell

development, data described in chapters II-IV describes our observations regarding altered
stromal cell function. These data suggest mechanisms by which chemotherapy alters the stromal
cell microenvironment consistent with diminished ability to support hematopoietic cell
development.
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ABSTRACT

It has become increasingly evident that chemotherapy regimens used to condition patients
prior to bone marrow transplantation damage the hematopoietic microenvironment as doseescalation reveals problems with hematopoietic recovery or engraftment. We have previously
demonstrated that bone marrow stromal cells exposed to dose escalated etoposide (VP-16) have
reduced support of CXCR4+ cell chemotaxis and diminished stromal cell derived factor-1
(CXCL12) in the supernatants.

Based on the identification of CXCL12 as a matrix

metalloproteinase-2 (MMP-2) substrate, we investigated potential dysregulation of MMP-2
expression or activity in chemotherapy-treated stromal cells. Stromal cell exposure to VP-16
resulted in an immediate, but transient, increase in MMP-2 followed by reduced MMP-2 protein
expression correlated with diminished CXCL12 protein and reduced chemotactic support.
Consistent with these observations, stromal cells derived from MMP-2 knockout mice had
significantly less chemotactic support of CXCR4+ cells than wild-type controls. Inhibition of
stromal cell MMP-2 activity by the specific inhibitor, OA-Hy, also reduced chemotactic support
and CXCL12 protein detected in supernatants.

VP-16-induced reduction of bone marrow

stromal cell support of hematopoietic cell migration was restored by supplementing cultures with
physiological levels of recombinant MMP-2 protein. These data suggest that MMP-2 is sensitive
to chemotherapy-induced stress, and may regulate stromal cell support of hematopoietic cell
chemotaxis through diverse mechanisms. Increased MMP-2 expression during the acute phase
of chemotherapy potentially mediates inactivation of CXCL12. Subsequently, chronic exposure
to chemotherapy, with the associated downregulation of MMP-2, interrupts CXCL12 release
from the extracellular matrix.
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INTRODUCTION

Chemotaxis of hematopoietic progenitor or stem cells to the bone marrow
microenvironment is essential for efficient hematopoietic recovery following bone marrow
transplantation1,2. CXCL12 is the primary chemokine released by bone marrow stromal cells
that promotes chemotaxis of transplanted progenitors to the bone marrow microenvironment

3,4

.

Following migration to the bone marrow, hematopoietic progenitors interact with stromal cells
which provide support to developing hematopoietic cells through the production of soluble
cytokines and chemokines, and adhesion molecules that facilitate physical interaction

5,6

. In

addition, bone marrow stromal cells deposit extracellular matrix that provides structural support
and stabilizes hematopoietic growth factors in concentrated niches

7-10

. CXCL12 is concentrated

and stabilized in the bone marrow microenvironment on heparin sulfated proteoglycans produced
by stroma 11.
Preparative regimens used prior to transplantation are aggressive, and have the potential
to damage the hematopoietic microenvironment

12-15

. One chemotherapeutic agent, etoposide

(VP-16), has previously been shown to negatively influence bone marrow stromal cell support of
hematopoiesis, in part, by diminishing vacsular cell adhesion molecule (VCAM-1) protein

16

.

Studies from our own laboratory have shown that VP-16 exposure also results in reduced ability
of stromal cells to support pro-B cell chemotaxis

17

. Together, these observations highlight the

vulnerability of stroma to chemotherapy damage, and prompted our investigation of the
mechanisms by which chemotherapy reduces efficiency of pro-B cell chemotaxis.
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MMPs have traditionally been considered in the context of extracellular matrix
regulation, however additional roles have been identified, including regulation of hematopoiesis
18-20

. Based on studies by others that documented the ability of MMP-2 to cleave and inactivate

CXCL12 21, we determined whether VP-16 exposure increased MMP-2 activity or expression in
bone marrow stromal cells, contributing to reduced chemotactic support. An immediate increase
in MMP-2 activity following initiation of VP-16 exposure was observed, that was pronounced
and transient. Bone marrow stromal cells exposed to greater than 5 hours of chemotherapy
expressed less MMP-2 protein than control stromal cells. Coincident with reduced MMP-2
expression is a reduction of CXCL12 protein and chemotactic support capacity. These
observations position MMP-2 as a factor in the bone marrow microenvironment that can respond
to external stresses, including chemotherapy, and influence support of hematopoietic
reconstitution through regulation of the CXCL12 gradient.
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MATERIALS AND METHODS

Reagents
VP-16 (etoposide, Bristol Laboratories, Princeton, NJ) was stored at a stock
concentration of 33.98 mM at -20°C and was diluted in α-Modification of Eagles Medium (αMEM, GIBCO, Grand Island, NY) immediately prior to use. MMP-2 Inhibitor I (Cis-9Octadeconyl-N-hydroxylamide, OA-Hy, Calbiochem, San Diego, CA) was reconstituted in
DMSO at 10mM immediately prior to use. Recombinant human MMP-2 (Biomol International
L.P., Plymouth Meeting, PA) and recombinant murine MMP-2 (R&D Systems Inc.,
Minneapolis, MN) were diluted in media at the indicated concentrations. Mouse anti-human
MMP-2 (Ab 3) monoclonal antibody was obtained from Calbiochem, Boston, MA.

Cell lines and culture conditions
Stromal cell cultures were initiated from human bone marrow from consenting donors,
with approval by the West Virginia University Institutional Review Board, as previously
described 15. All primary bone marrow stromal cells cultures were initiated from donors with no
previous chemotherapy exposure. Bone marrow stromal cells were maintained in α-MEM
supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 1% L-glutamine (GIBCO,
Grand Island, NY), 1% Penicillin/Streptomycin (Sigma, St. Louis, MO), and 0.1% 2-betamercapthanol (Sigma, St. Louis, MO).
Murine bone marrow stromal cell line S10 was provided by Dr. Kenneth Dorshkind
(University of California Los, Angeles). Characterization and maintenance of S10 has been
previously described in detail

22

. S10 stromal cells were grown to confluence in α-MEM
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supplemented with 2.5% fetal bovine serum, 1% L-glutamine (GIBCO, Grand Island, NY), 1%
Penicillin/Streptomycin (Sigma, St. Louis, MO), and 0.1% 2-beta-mercapthanol (Sigma, St.
Louis, MO).
Murine pro-B cell clone C1.92 was provided by Dr. Kenneth S. Landreth (West Virginia
University). Derivation of C1.92 has been previously described 23. C1.92 was maintained in the
presence of the bone marrow stromal cell line S-10 and 50U/mL recombinant murine IL-7 (mIL7, Biosource International, Westlake Village, CA).
MMP-2-/- and wild type (WT) bone marrow stromal cells were initiated from femurs
isolated from C57BL/6 WT and C57BL/6 MMP-2 knockout mice (kindly provided by Dr. Farrah
Kheradmand; Baylor College of Medicine) 24. WT and MMP-2-/- stromal cells were cultured in
α-MEM supplemented with 2.5% fetal bovine serum, 1% L-glutamine (GIBCO, Grand Island,
NY), 1% Penicillin/Streptomycin (Sigma, St. Louis, MO), and 0.1% 2-beta-mercapthanol
(Sigma, St. Louis, MO).

Gelatin Zymography
Bone marrow stromal cells supernatants were collected following 2 hours treatment in
serum free α-MEM (GIBCO, Grand Island, NY) with 100μM VP-16 (Bristol Laboratories,
Princeton, NJ). Supernatants were concentrated 10X using Amicon® Ultra-15 Centrifugal
Filters (Millipore, Billerica, MA). Samples were resolved in SDS-PAGE gels containing
1mg/mL gelatin (Sigma, St. Louis, MO). Following electrophoresis, gels were incubated for 30
minutes in 2.5% Triton-X-100 (Mallinckrodt, Inc., Paris, KY) and subsequently incubated
overnight at 37°C in 1X developing buffer (1.2% Tris Base, 6.3% Tris HCl, 11.7% NaCl, 0.7%
CaCl,0 .2% Brij 35). Gels were then stained with 0.5% Coomassie Blue R-250 (Bio-Rad
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Laboratories, Richmond, CA) for 30 minutes at room temperature and then destained (50%
Methanol, 10% acetic acid, 40% dH20) until clear bands were detected indicative of MMP-2
and/or MMP-9.

Western blot analysis
Confluent bone marrow stromal cells were treated with 25-100μM VP-16 for 24 hours.
To determine protein stability, confluent stromal cells were set up in duplicate and treated with
both 100µM VP-16 and 25:g/mL cycloheximide or VP-16 alone for 2 to 24 hours. Supernatants
were collected following treatment and concentrated 10x using Amicon® Ultra-15 Centrifugal
Filter Devices (Millipore, Billerica, MA). Media was centrifuged at 3,000xg for 10 minutes at
room temperature. Concentrated supernatants were resolved on SDS-PAGE gels and transferred
to nitrocellulose membranes (Schleicher & Schuell bioscience, Inc., Keene, NH). Membranes
were blocked in TBS/5% nonfat dry milk/0.1% Tween-20 at room temperature for 1 hour and
probed with mouse anti-human MMP-2 monoclonal antibody. Proteins were detected by
incubation with horseradish peroxidase-conjugated secondary antibody and visualized with ECL
reagents (Amersham, Pharmacia Biotech, Piscataway, NJ).

Confocal Microscopy
Bone marrow stromal cells were grown to confluence on glass coverslips and treated with
100µM VP-16 for 24 hours. Following treatment, stromal cells were rinsed in autoclaved 1X
PBS and fixed in 1:1 methanol:acetone for 20 minutes. Non-specific antibody binding was
blocked by incubation of stroma for 15 minutes in autoclaved 1X PBS/ 5% BSA. Intracellular
MMP-2 was evaluated by incubation of stromal cells with MMP-2 monoclonal antibody for 1 hr.
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PE conjugated secondary antibody was then added to stroma for 60 minutes and coverslips were
inverted on slides and evaluated by confocal microscopy (Zeiss LSM 510, Thornwood, NY).

RNA Isolation
Total RNA was isolated from bone marrow stromal cells using the Micro-to-Midi Total
RNA Isolation kit following the recommendations of the manufacturer (Invitrogen, Carlsbad,
CA). Pelleted stromal cells were lysed by centrifugation through QIA shredder Spin Columns
(QIAGEN Inc, Santa Clarita, CA). RNA was treated with 1U DNAse for 30 minutes at 37°C and
samples were quantitated at 260nm (GENESYS-10UV, Spectronic Unicam, Rochester, NY).

PCR
To evaluate MMP-2 and β-actin RNA levels, semi-quantitative “One-Step” RT-PCR
(QIAGEN Inc., Valencia, CA) was completed using 0.1µg RNA isolated from untreated or VP16 treated bone marrow stromal cells. Reverse transcription was completed by incubation of
samples at 42°C for 90 minutes and amplification initiated by a hot start at 95°C for 5 minutes,
followed by 35 cycles of 94°-1 minute, 55°-1 minute, and 72°-1 minute (Perkin-Elmer GeneAmp
PCR System 9600). Actin and MMP-2 primers (0.1µg/sample) were added to each reaction.
Actin specific primers included 5’TGACGGGGTCACCCACACTGTGCCCATCTA-3’ and
5’TAGAAGCATTTGCGGTGGACGATGGAGGG-3’ (Stratagene, La Jolla, CA) to generate an
amplicon of 661 base pairs. MMP-2 primers were 5’-GGCCCTGTCACTCCTGAGAT3’ and
5’-GGCATCCAGGTTATCGGGGA-3’ (Biosource International, Camarillo, CA) to generate an
amplicon of 474 base pairs. MMP-2 to actin ratios were quantitated by EagleSight Version 3.21
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(Stratagene, La Jolla, CA) densitometric analysis. The linear range of amplification was
determined for each primer set prior to use.

RNAse protection assay
Confluent bone marrow stromal cell layers were treated with 25, 50 or 100μM VP-16 for
24 hours. RNAse protection assays were performed using an RPAIII kit according to the
protocol of the manufacturer (Ambion Inc., Austin, TX). 10µg of RNA from each sample was
hybridized to 32P-labeled MMP-2, GAPDH, and L-32 specific probes. Anti-sense 32P-RNA
probes were generated using T7 RNA polymerase-directed synthesis from RiboQuant DNA
templates (PharMingen, San Diego, CA). Nucleic acids were treated with RNAse A and T1 to
digest unhybridized sequences. Protected RNA fragments that corresponded to MMP-2 and
GAPDH were visualized by exposure to Phospho Imager cassettes (Molecular Dynamics,
Sunnyvale, CA). MMP-2 band intensities were normalized to GAPDH or L-32 controls in each
treatment group.

CXCL12 and MMP-2 ELISA
Confluent bone marrow stromal cells were treated with 1µM OA-Hy or 100µM VP-16
for 24 hours. 100µL of 24-hour stromal cell conditioned supernatant was collected from each
well to evaluate CXCL12 or MMP-2 protein by ELISA, following the recommendations of the
manufacturer (R&D Systems, Inc, Minneapolis, MN). All samples were evaluated in triplicate.
Colorimetric values were read on a plate reader (Biotek Instruments, Inc., Winoski, VT) and
analyzed by the KC Junior software with reference wavelengths set at 450nM and correction
wavelength set at 540nM.
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Intracellular CXCL12 Staining
Bone marrow stromal cells were grown to confluence and exposed to 100μM VP-16,
1µM OA-Hy or DMSO for 24 hours. Following treatment, stromal cells were trypsinized,
collected, and fixed in 10% formaldehyde for 30 minutes. Stromal cells were rinsed in 1X PBS
and permeabolized in 70% EtOH for 30 minutes on ice. To prevent non specific antibody
binding, stromal cells were blocked in PBS/5% BSA for 15 minutes and subsequently incubated
with 2ug of CXCL12 specific antibody or isotype control for 20 minutes. PE conjugated
secondary antibody was added to stromal cells for 20 minutes. Stromal cells were rinsed,
evaluated by flow cytometry and data were analyzed using CellQuest software (Becton
Dickinson, San Jose, CA).

Chemotaxis assay
Confluent bone marrow stromal cell layers, grown in 24-well tissue culture plates
(Becton Dickinson, Franklin Lakes, NJ), were treated with 100µM VP-16, 1µM OA-Hy, or left
untreated for 24 hours. Stromal cells were then rinsed with fresh medium and 350µL of medium,
or medium supplemented with 10ng/mL recombinant murine MMP-2 or 25ng/mL recombinant
human MMP-2 was placed in the bottom chamber of each well for 2 hours. In addition,
C57BL/6 WT or MMP-2-/- bone marrow stromal cells were grown in 350µL α-MEM in 24-well
tissue culture plates for 24 hours. Following incubation, transwells with 5µ pores (Corning Inc.,
Corning, NY) containing 1.5x105 C1.92 were placed into each well. Following incubation at
37° C for 4 hours, cells migrating to the lower chamber were enumerated by flow cytometry
(number of events/30-second collection). Recombinant CXCL12 (100ng/mL R&D Systems Inc.,
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Minneapolis, MN), and medium alone served as the positive and negative control respectively.
All samples were evaluated in triplicate.

Statistical Analysis
Statistical analysis was performed using Student’s T-test to detect differences among
means (SigmaStat Version 4.0 software, SPSS Inc., Chicago, IL). All statistical comparisons
represent treated samples compared to control levels. Statistically significant differences are
indicated by and asterisk on appropriate graphs.
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RESULTS

MMP-2 expression is regulated distinctly during acute and chronic VP-16 exposure.
To evaluate alterations in MMP-2 protein, we performed gelatin zymography on
supernatants from bone marrow stromal cells that were exposed to VP-16. Following treatment,
stromal cell MMP-2 levels increased at 30 minutes and subsequently began to diminish
following 5 hours of VP-16 exposure (Figure 1A).
To determine whether VP-16 alters bone marrow stromal cell production of MMP-2
during long-term exposure, we evaluated several primary human bone marrow stromal cell lines
by ELISA following 24 hours of exposure to VP-16.

MMP-2 protein was diminished in

supernatants of stromal cells to approximately 12% to 58% of that in untreated controls (Data not
shown). MMP-2 protein was also evaluated by western blot and the amount of active and latent
MMP-2 protein in concentrated supernatants was determined to be reduced by VP-16 exposure
compared to untreated controls (Figure 1B). MMP-2 protein was not altered in stromal cells
treated with VP-16 solvent control (Data not shown). Reduction of MMP-2 protein in stromal
cells exposed to VP-16 for 24 hours was not due to intracellular accumulation (Figure 1C) or
reduced protein stability (Figure 1D).
In contrast to MMP-2 protein, MMP-2 mRNA was not reduced during VP-16 exposure.
Semi-quantitative RT-PCR (Figure 2A) illustrates that stromal cells treated with 100μM VP-16
do not have diminished MMP-2 mRNA. This result was confirmed by RNAse protection
(Figure 2B).

MMP-2 protein is necessary for optimal stromal cell support of chemotaxis.
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To determine if MMP-2 protein is necessary for bone marrow stromal cell support of proB cell chemotaxis we compared control stromal cells with stromal cells treated with OA-Hy or
Bone marrow stromal cells derived from WT and MMP-2-/- mice. Addition of OA-Hy to
stromal cells resulted in approximately 50% reduction in the ability of human primary (P151)
and murine S-10 bone marrow stromal cells to support C1.92 pro-B cell chemotaxis (Figure 3A).
Direct addition of OA-Hy to CXCL12 did not reduce support of chemotaxis (Figure 3A). MMP2-/- bone marrow stromal cells also had diminished ability to support chemotaxis compared to
WT control stromal cells (Figure 3B). Addition of recombinant CXCL12 restored MMP-2-/stromal cell support of chemotaxis to approximately 93% of control stromal cells. (Figure 3B).

CXCL12 protein is diminished in supernatants following MMP-2 inhibition.
To determine whether MMP-2 is required for release of CXCL12 protein into
supernatants of adherent bone marrow stromal cells, stromal cells were treated with 1µM OA-Hy
for 24 hours. CXCL12 protein was diminished in OA-Hy treated stromal cell supernatants
compared to DMSO solvent control treated stromal cells (Figure 4A). The reduction of CXCL12
in supernatants was not due to intracellular accumulation of CXCL12 protein (Figure 4B).
CXCL12 mRNA was not altered by OA-Hy treatment, determined by RT-PCR (Data not
shown).

Recombinant MMP-2 protein restores VP-16 treated bone marrow stromal cell support of
chemotaxis.
To determine whether addition of MMP-2 protein could restore VP-16 treated bone
marrow stromal cell support of chemotaxis; we first determined the amount of MMP-2 protein
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that primary human stromal cell line (P156) and C57BL/6 stromal cells produced at steady state
(Data not shown). Based on our ELISA results, we added 25ng/mL rhMMP-2 to VP-16-treated
P156 bone marrow stromal cells or 10ng/mL rmMMP-2 to C57BL/6 MMP-2-/- bone marrow
stromal cells to approximate physiological levels. Addition of MMP-2 restored VP-16-treated
and MMP-2-/- stromal cell support of chemotaxis to greater than 100% of untreated human P156
stromal cells (Figure 5A) and 85% of that supported by WT murine stromal cells (Figure 5B).
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DISCUSSION

In the current study we found that bone marrow stromal cell MMP-2 is affected
differentially by acute and chronic exposure to VP-16.

Increased MMP-2 expression was

transient in VP-16 stromal cells. Subsequent to the acute response, MMP-2 protein was reduced
when stromal cells were exposed to VP-16 for longer periods of time. The consequence of
chronic exposure of stromal cells to VP-16 is the main focus of the current study. Our data
suggest that chemotherapy down regulates MMP-2 protein expression and disrupts CXCL12
supported chemotaxis, potentially, by inhibiting CXCL12 release from the stromal cell surface.
This novel role for MMP-2 in CXCL12 regulation broadens the context in which MMPs may
influence hematopoiesis. Further, it contributes to our understanding of factors that may impact
on chemotactic support by the bone marrow microenvironment following aggressive
chemotherapy.
We have previously shown that VP-16 induces many alterations in bone marrow stromal
cells that result in disrupted support of hematopoiesis

16,17

. In the current report, we show that

VP-16 treatment (100μM) increases, and then subsequently reduces, the amount of MMP-2
protein detected in stromal cell supernatants (Figure 1). VP-16 exposure rapidly increases
stromal cell ROS generation, potentially allowing for immediate activation of MMP-2 through
conformation changes resulting in auto-catalytic cleavage of MMP-2’s pro-domain (Chapter III).
The mechanism of diminished MMP-2 protein during chronic VP-16 exposure is not due to
reduced MMP-2 mRNA or intracellular accumulation of protein (Figure 1, 2). Further, the
stability of MMP-2 protein is not reduced by VP-16 (Figure 1).
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Based on this study, future investigations will focus, in part, on disruption of translation
efficiency of MMP-2 transcripts in VP-16 treated bone marrow stromal cells. In other models
VP-16 has been shown to blunt phosphorylation of Eukaryotic Initiation Factor 4α (EIF4α)25
which is necessary for MMP-2 translational initiation to occur 26. Additionally, VP-16 treatment
of Swiss 3T3 fibroblast cells increased association of cap binding protein eIF-4E with its
inhibitory binding protein 4E-BP

27

.

Unsequestered eIF-4E is also necessary for efficient

translation of MMP-2 message 26. These observations suggest that disrupted translation may be
one consequence of VP-16-induced damage, resulting in potentially diverse effects on stromal
cell function.
Initial observations that preceded this study indicated that the addition of OA-Hy to
established bone marrow stromal cell pro-B cell co-cultures resulted in diminished adhesion of
pro-B cells to stromal cells, a subsequent accumulation of pro-B cells in G0/G1 phase of cell
cycle, and increased apoptosis (Data not shown). Clearly, the effects of OA-Hy on the co-culture
may be due to a direct effect of MMP-2 inhibition on stromal cell function, pro-B cell
proliferation or survival, or a combination of effects on both cell types. The current study was
aimed at isolating the effects of diminished MMP-2 on stromal cell influence of hematopoietic
support capacity.
B lymphopoiesis has not been evaluated in MMP-2-/- mice. However, MMP-2-/- mice
have been used to study antibody induced asthma, arthritis, and Experimental Autoimmune
Encephalomyelitis (EAE)

28-30

. Increased incidence of EAE in MMP-2-/- mice is due to an

increase in T-cell MMP-9 expression. B cells were not evaluated in this model so no conclusion
can be drawn regarding B lymphopoiesis in the absence of MMP-2 in vivo 28. However, it has
become increasingly evident that MMPs influence hematopoietic cell support in the bone
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marrow microenvironment from other studies. One report indicates that MMP-9 is required to
release soluble Kit-ligand within the bone marrow microenvironment, which regulates stem cells
movement from quiescent to proliferative niches

31

.

This study is just one that provides

precedent for MMPs function within the bone marrow microenvironment as a regulator of
growth-factor availability.
To determine whether diminished MMP-2 expression in bone marrow stromal cells
exposed to VP-16 contributes to reduced support of chemotaxis, we treated stromal cells with
OA-Hy, and quantitated the ability of treated stroma to support pro-B cell chemotaxis.
Consistent with VP-16 exposure, MMP-2 inhibition by OA-Hy diminished stromal cell support
of chemotaxis (Figure 3A). Because the use of chemical inhibitors has the limitation of nonspecific effects, we chose to further investigate MMP-2 in a more specific manner. To do so, we
established bone marrow stromal cells from MMP-2 knockout mice. MMP-2-/- stromal cells used
in this study were established from the only MMP-2-/- mice currently available to our laboratory
(femurs generously provided by Dr. Farrah Kheradmand). This MMP-2-/- was generated on the
C57BL/6 background. We have previously noted that C57BL/6 bone marrow stromal cells are
very resistant to chemotherapy and display enhanced support of pro-B cells when compared to
human or Balb/c derived bone marrow stromal cells (unpublished data). MMP-2-/- stromal cells
were less able to support pro-B cell chemotaxis than stromal cells established from wild-type
control mice, further supporting a role for MMP-2 protein in CXCL12 directed migration of proB cells (Figure 3B).
OA-Hy treated stromal cells secrete less CXCL12 protein than controls (Figure 4A),
however, we have confirmed that this is not due to intracellular accumulation of the CXCL12
protein (Figure 4B). This suggests that MMP-2 may regulate release of CXCL12 from the
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stromal cell surface.

Potentially, when MMP-2 protein is below physiological levels, as

observed following VP-16 exposure or OA-Hy treatment, proteoglycan bound CXCL12 is not
efficiently released and an optimal chemotactic gradient is not established. Consistent with a
role for MMPs in regulating chemokine gradients, MMP-2-/- mice used in an antibody-induced
asthma model have inflammatory cells sequestered in lung parenchyma resulting in asphyxiation.
Notably, MMP-2 protein is required for release of eotaxin chemokine (CCL11)

24

which is

necessary for directed migration of inflammatory cells out of the lung parenchyma.
Restoration of diminished bone marrow stromal cell chemotactic support by VP-16
treated stroma occurred only when recombinant MMP-2 protein was added back at physiological
levels (Figure 5B). Levels that exceeded baseline decreased chemotactic support of stromal cells.
A previous report indicates that MMP-2 can cleave and inactivate CXCL12, resulting in reduced
chemotactic support

21

. Our data suggest that inactivation of CXCL12 by MMP-2 may occur

when active MMP-2 is elevated during the acute response to chemotherapy. This may reduce the
concentration of active CXCL12 in the bone marrow microenvironment, contributing to
diminished recruitment of CXCR4+ pro-B cells. Consistent with the report noted above, we
found that increased MMP-2 diminished CXCL12 supported chemotaxis in a dose responsive
manner (Data not shown). Our data suggest that at physiological levels bone marrow stromal
cell MMP-2 may release proteoglycan bound CXCL12 establishing a chemotactic gradient,
while inappropriately high levels observed during tissue damage inactivate CXCL12 protein.
Potentially, dysregulation of MMP-2 that occurs during VP-16 exposure may contribute to
diminished bone marrow stromal cell chemotactic support by this combination of effects on
CXCL12 activity and availability.
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FIGURE LEGENDS

Figure 1. MMP-2 protein is dysregulated in bone marrow stromal cells exposed to VP-16. (A)
Stromal cell supernatants were conditioned in serum-free medium for 8 hours. At each time
point (30 minutes – 8 hours) 100:M VP-16 was added to the conditioned stromal cell media.
After 8 hours the supernatants were collected and gelatin zymography performed to detect
MMP-2. (B) Supernatants were collected from VP-16 treated bone marrow stromal cells and
concentrated as described in Materials and Methods. MMP-2 monoclonal antibody was used to
detect MMP-2 protein in VP-16 treated groups compared to supernatants collected from
untreated control stromal cells. Data are representative of three independent experiments. (C)
Bone marrow stromal cells treated with 100µM VP-16 for 24 hours were fixed and stained with
MMP-2 monoclonal antibody and subsequently incubated with PE-tagged secondary antibody.
Fluorescence was detected by confocal microscopy. (D) Confluent bone marrow stromal cells
were treated with either VP-16 or VP-16 and cycloheximide for 2-24 hours. At each time point
the supernatants were collected, concentrated 10X, and subjected to western blot with antibody
specific to MMP-2.

Figure 2. MMP-2 mRNA is not diminished following VP-16 exposure. (A) MMP-2 mRNA is
not altered by VP-16 treatment of bone marrow stromal cells. Stromal cells were treated for the
indicated times with 100uM VP-16. Semi-quantitative RT-PCR was performed to estimate the
amount of MMP-2 message in each sample relative to β-actin. Representative data from three
independent experiments are shown. (B) Bone marrow stromal cells were treated with 50 or
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100µM VP-16 for 24 hours, RNA was extracted, and RNAse protection assay was completed
with probes specific for MMP-2 and GAPDH sequences.

Figure 3. MMP-2 is necessary for optimal bone marrow stromal cell support of pro-B cell
chemotaxis. (A) Murine S10 or P151 primary human bone marrow stromal cells were left
untreated or treated with 1µM OA-Hy for 24 hours in the bottom chamber of a transwell plate.
Following 4 hours of chemotaxis towards stromal cells, media, or rCXCL12, the number of
C1.92 cells that migrated to the bottom chamber was evaluated by flow cytometry. (B) C57BL/6
WT and C57BL/6 MMP-2-/- bone marrow stromal cells were evaluated for their ability to
support chemotaxis of C1.92 cells. Following 4 hours of incubation, C1.92 cells were collected
from lower wells that contained either adherent WT or MMP-2-/- stromal cell layers. C1.92 cells
that migrated to the bottom chamber were enumerated by flow cytometry (p<.05).

Figure 4. CXCL12 protein is diminished in the supernatants of bone marrow stromal cells with
diminished MMP-2 protein levels. (A) Stromal cells were either untreated, or treated with 1µM
OA-Hy, DMSO, or 100µM VP-16 for 24 hours. Supernatants were evaluated by a CXCL12
specific ELISA (p<.01). (B) CXCL12 intracellular staining was performed on stromal cells
exposed to 1µM OA-Hy or DMSO for 24 hours. All samples were compared to isotype controls.

Figure 5.

Recombinant MMP-2 protein restores VP-16 treated bone marrow stromal cell

support of chemotaxis. P156 primary stromal cells were treated with 100μM VP-16 for 24 hours
and C57BL/6 MMP-2-/- stromal cells were cultured for 24 hours prior to the addition of CXCR4+
cells to the top chamber. P156 stromal cells were then rinsed and either 10 mg/mL murine or 25
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ng/mL human recombinant MMP-2 was added in 350μL of media to C57BL/6 MMP-2-/- or P156
6

stromal cells respectively for 2 hours. 5μm transwells were placed on top of the cells and 1x10

C1.92 were evaluated for their ability to migrate into the bottom chamber over a 4-hour period
(p<.05).
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Figure 1. MMP-2 protein is dysregulated in bone marrow stromal cells exposed to VP-16.
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Figure 2. MMP-2 mRNA is not diminished following VP-16 exposure
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Figure 3. MMP-2 is necessary for optimal bone marrow stromal cell support of pro-B cell
chemotaxis.
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Figure 4. CXCL12 protein is diminished in the supernatants of bone marrow stromal cells with
diminished MMP-2 protein levels
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Figure 5. Recombinant MMP-2 protein restores VP-16-treated bone marrow stromal cell support
of chemotaxis.
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ABSTRACT

Dose-escalated chemotherapy has proven utility in a variety of treatment settings,
including preparative regimens prior to bone marrow or hematopoietic stem cell transplantation
(BMT/HSCT). However, the potential damage imposed by aggressive regimens on the marrow
microenvironment warrants further investigation. In the present study, we tested the hypothesis
that dose-escalated chemotherapy, with etoposide as a model chemotherapeutic agent, activates
the transforming growth factor beta-1 (TGF-β1) signaling pathway in bone marrow stromal cells.
Following high-dose etoposide exposure in vitro, Smad3 protein was phosphorylated in a timeand dose dependent manner in marrow derived stromal cells, coincident with the release of
active and latent TGF-β1 from the extracellular matrix (ECM). Phosphorylation was modulated
by p38 kinase, with translocation of Smad3 from the cytoplasm to the nucleus subsequent to its
phosphorylation. Etoposide-induced activation of TGF-β1 followed the generation of reactive
oxygen species (ROS) and required MMP-2 protein availability. Chemotherapy effects were
diminished in MMP-2-/- knockout stromal cells and TGF-β1 knockdown siRNA-transfected
stromal cells, in which phosphorylation of Smad3 was negligible following etoposide exposure.
Stable transfection of a human MMP-2 cDNA into bone marrow stromal cells resulted in
elevated phosphorylation of Smad3 during chemotherapy. These data suggest TGFβ1/p38/Smad3 signaling cascades are activated in bone marrow stromal cells following doseescalation chemotherapy, and may contribute to chemotherapy-induced alterations of the marrow
microenvironment.
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INTRODUCTION

The bone marrow microenvironment serves as the primary site of normal postnatal
hematopoiesis and supports hematopoietic recovery following myelosuppressive chemotherapy
or irradiation-induced injury of the immune system [1, 2]. Hematopoietic reconstitution requires
efficient migration of transplanted stem/progenitor cells to the bone marrow and relocation to
stromal cell niches in this microenvironment [3]. The effects of preparative regimens on the
marrow microenvironment remain an area requiring further investigation. The assumption that
aggressive chemotherapy spares the bone marrow microenvironment grows increasingly more
suspect as dose-escalation of chemotherapy reveals unexpected problems with hematopoietic
recovery [4, 5]. The dilemma remains maintaining efficacy of tumor eradication while reducing
damage to the microenvironment.
Of the signaling molecules in the bone marrow microenvironment that may be involved in
chemotherapy-induced bone marrow damage, TGF-β1 is specifically noteworthy. TGF-β1
regulates a variety of biological responses including angiogenesis, chemotaxis, cell cycle
progression, differentiation and apoptosis of target cells in a context- and cell-specific manner [6,
7]. TGF-β1 is also involved in regulating extracellular matrix remodeling, collagen gene
expression and degradation of matrix proteins during the processes of tissue injury and repair [6,
7]. Up-regulated expression or activation of TGF-β1 at sites of injury is associated with
proliferation of fibroblasts, progressive fibrosis, and subsequent organ dysfunction in diverse
systems including kidney, liver and lung [8-11]. In contrast to its promotion of mesenchymal cell
proliferation and survival, TGF-β1 is a potent inhibitor of hematopoietic stem cells [12, 13].
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TGF-β1 is initially synthesized as a large precursor which is processed to a mature protein
during secretion. Following secretion, mature TGF-β1 (25 kD) non-covalently associates with its
N-terminal propeptide, the 75 kD latency-associated protein (LAP) [14]. The TGF-β1-LAP
complex predominantly binds to a latent TGF-β1-binding protein (LTBP) which mediates
deposition of the latent complex (230 kD and 195 kD) to the extracellular matrix (ECM) [14].
Release of mature TGF-β1 from the latent complex can be accomplished by different
mechanisms such as proteolytic cleavage of LAP by plasmin [15], deglycosylation of LAP [16],
or interaction with thrombospondin-1 [17], platelet [18], or integrin α4, β6 [19]. Following TGFβ1 ligand binding, TGF-β1 receptor II recruits and activates TGF-β1 I receptor, which in turn
phosphorylates and activates the R-Smads including Smad2 or Smad3 [20]. Phosphorylated RSmads homodimerize, form a transcriptional complex with Smad4, and translocate into the
nucleus to regulate target gene expression [20].
Data presented in the current study suggest that the TGF-β1/p38/Smad3 signaling cascades
are activated through ROS-mediated MMP-2 activity in bone marrow stromal cells during
etoposide chemotherapy. Increased availability of active TGF-β1 has the potential to alter
stromal cell function through regulation of diverse Smad-driven gene expression in stromal cells.
Moreover, release of TGF-β1 from extracellular matrix during chemotherapy may also directly
regulate growth and proliferation of transplanted hematopoietic stem cells. This in vitro model
provides a setting in which we can further delineate the effects of chemotherapy on marrow
stromal cells and evaluate the role of TGF-β1 in influencing hematopoietic recovery following
transplantation.
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MATERIALS AND METHODS

Cell cultures
HS-27A human bone marrow derived stromal cells [21] (ATCC# CRL-2496) were
maintained in alpha-modification of Eagle’s medium (α-MEM, GIBCO, Grand Island, NY) with
supplements as recommended by the ATCC (Manassas, VA). Ped604, P148 and P156 are
primary bone marrow stromal cells derived from consenting donors with WVU IRB approval.
Establishment of bone marrow stromal cells and their characterization by our laboratory have
been previously described in detail [22]. Bone marrow aspirates from MMP-2 knockout (MMP2-/-, KO) or wild type (MMP-2+/+, WT) C57BL/6 mice were generously provided by Dr. Farrah
Kheradmand [23], Baylor College of Medicine. Murine bone marrow stromal cell line S-10
(provided by Dr. Kenneth Dorshkind (University of California at Los Angeles, CA), and stromal
cell- and IL-7 dependent murine pro-B cell line, C1.92, has been previously described [24].

Chemotherapeutic and other chemical agents
Etoposide (VP-16, Bristol Laboratories, Princeton, NJ) was stored at a stock concentration of
33.98 mM and was used as the model chemotherapeutic agent throughout the experiments. A
final concentration of 100 μM was utilized to mimic pre-transplant clinical treatment [25].
Cytarabine (Ara-C, Sigma, St. Louis, MO) was reconstituted at 10 mg/mL and stored at -20°C.
Doxorubicin

(Dox,

3

mM)

was

purchased

from

Gensia

(Irvine,

CA)

and

4-

hydroperoxycyclophosphamide (4-HC, 10 mg/mL) was a gift from Dr. T. Ball (University of
California, San Diego). Danunorubicin (DNR, Sigma), Melphalan (Mel, Sigma) and Vincristine
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(VCR, Sigma) were reconstituted at 10 μg/μL immediately prior to use. Experimental
concentrations of chemotherapeutic drugs are noted in appropriate figure legends.
The MMP-2 inhibitor cis-9-octadecenoyl-N-hydroxylamide (OA-Hy), Erk1/2 kinase
inhibitor U0126, p38 kinase inhibitor SB220025, and JNK/SAPK inhibitor SP600125 were
purchased from Calbiochem (La Jolla, CA). Reactive oxygen species scavenger N-acetylcysteine (NAC) was purchased from Sigma. Recombinant active MMP-2 and pro-MMP-2 were
purchased from BioMol (Plymouth Meeting, PA) and Calbiochem, repectively. Recombinant
human TGF-β1 (rh-TGF-β1) was obtained from R&D Systems (Minneapolis, MN).
In the indicated experiments, stromal cells were preincubated with 1μM OA-Hy for 30 mins,
or 250ng/mL active or pro-MMP-2 for 15 mins prior to exposure to chemotherapy for 1 hour.
For in vitro activation of MMP-2, pro-MMP-2 was incubated with 10 μM hydrogen peroxide
(H2O2, 8.8N, Sigma) at 37 °C for 15 minutes immediately prior to use. Where indicated, stromal
cells were pretreated with 10μM U0126, 20μM SB220025 or 5μM SP600125 for 30 minutes
prior to etoposide exposure for an additional 1 hour.

Transfection of murine stromal cells with human MMP-2
A 2,119-bp EcoRI cDNA fragment encoding the full-length human MMP-2 was cut from
the entry plasmid pBR322-MMP-2-amp(+) (ATCC#65016) and inserted into the multiple
cloning site of the mammalian expression plasmid pUSE-CMV-neo (Upstate, Placid, NY).
Subcloning was carried out following purification using the MiniElute gel purification kit
(Qiagen Sciences, MD) with the cDNA ligated with T4 DNA liagase (Invitrogen, Carlsbad, CA).
Transfection of stromal cells with the pUSE-MMP-2-neo construct or its empty vector control
pUSE-CMV-neo was conducted following the protocols described previously [26,27]. Briefly,
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16 hours prior to transfection, S-10 stromal cells were cultured in α-MEM supplemented with
5% FBS with no antibiotics (transfection growth medium, TGM). Plasmid DNAs and
Lipofectamine 2000 (Invitrogen) were diluted with Opti-MEM (Invitrogen) and mixed at
variable ratios at room temperature for 20 minutes. Murine stromal S-10 cells were transfected
with either the vector or MMP-2 construct followed by G418 selection (0.5 mg/mL). Stable
clones expressing both the human MMP-2 and neomycin resistant gene product, neomycin
phosphotransferase II (NPT II), or the NPT II alone were selected for further experiments. These
are designated SM-8 and SV-2 respectively.

TGF-β1 knockdown by siRNA
For transient TGF-β1 siRNA transfection, Lipofectamine 2000 and non-targeting dsRNA
control or TGF-β1 knockdown siRNA (Dharmacon, Boulder, CO) were diluted and combined.
HS-27A and P148 human stromal cells were cultured in TGM overnight and transfected with 50150 nM TGF-β1 knockdown siRNA or control dsRNA. Control siRNA was consistently used at
the highest concentration of TGF-β1 siRNA in all experiments. 48 hours post-transfection, TGM
was replaced with serum-free medium and stromal cells were treated with 100 μM etoposide for
1 hour. Stromal cell supernatants and cell pellets were collected for ELISA, zymography or
Western blot analyses.

Quantitation of active and total TGF-β1 by ELISA
Quantitation of the release of active and total TGF-β1 from stromal cell ECM during
chemotherapy was measured by ELISA according to the recommendations of the manufacturer
(R&D systems). Briefly, confluent stromal cells were plated in 6-well plates in serum-free
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medium overnight. Following exposure to 0-100μM of etoposide for 1 hour, or 100μM etoposide
for 5 minutes to 6 hours, stromal cell supernatants were collected. Ten minutes prior to each
treatment, 0.5μg/mL anti-TGF-β1 antibody was added to each well to stabilize the released TGFβ1. Supernatants were acidified with 1.0 N HCl solution and neutralized with 1.2 N NaOH/0.5 M
HEPES solution immediately prior to assay to measure total TGF-β1. For quantitation of
active/free TGF-β1, supernatants were directly subjected to ELISA without acid activation. Both
acidified and non-acidified samples were measured in triplicate and colorimetric development
was determined at 450 nm with correction wavelength at 540 nm on a multi-well plate reader
(BioTek Instruments).

Antibodies and Western blot analysis
Rabbit polyclonal anti-phospho-Smad3 (Ser433/435), rabbit monoclonal anti-phosphop38 kinase (Thr180/Tyr182), rabbit monoclonal anti-phospho-Erk1/2 MAPK (Thr202/Tyr204),
and rabbit monoclonal anti-phospho-JNK/SAPK (Thr183/Tyr185) were purchased from Cell
Signaling Technology (Beverly, MA). Mouse monoclonal anti-p38 kinase, and rabbit polyclonal
anti-JNK2 antibodies were also from Cell Signaling Technology. Rabbit polyclonal anti-Erk2
and rabbit polyclonal anti-Erk1 were from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse
monoclonal anti-Smad3 was from BD Transduction Laboratories (San Diego, Ca). Mouse
monoclonal anti-human TGF-β1, LAP/TGF-β1 and LTBP-1/TGF-β1 antibodies were obtained
from R&D Systems. Rabbit polyclonal anti-NPT II antibody was purchased from Upstate.
Cells were lysed in complete cell lysis buffer (CCLB, 50 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 1% TritonX-100, 0.25% Na-deoxycholate, 1 mM EDTA, and 1 mM NaF, 1mM DTT, 1
mM PMSF, 1 mM activated Na3VO4, 1g /mL aprotinin, 1µg /mL leupeptin, and 1µg /mL
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pepstatin) on ice for 15 minutes. Following centrifugation at 14,000 rpm for 15 minutes,
supernatants were collected and protein concentration determined using the BCA protein assay
(Pierce, Rockford, IL). Proteins were resolved on SDS-PAGE gels and transferred to
nitrocellulose membranes. Membranes were blocked in TBS/5%/0.05% Tween-20 nonfat dry
milk and probed with the indicated primary antibodies. Following incubation with HRPconjugated secondary antibodies, signal was visualized using ECL reagents (Amersham,
Piscataway, NJ).

Immunoprecipitation of TGF-β1
Confluent stromal cells were rinsed with serum-free α-MEM, then re-cultured in serumfree media. Anti-human TGF-β1, LAP/TGF-β1 and LTBP-1/TGF-β1 antibodies were added at a
final concentration of 3μg/mL for 15 minutes prior to addition of etoposide for 1 hour.
Supernatants were collected and combined with protein A/G agarose beads (Santa Cruz
Biotechnology) at 4 C° for 4 hours. The immunoprecipitates were washed with CCLB and
heated to 100 C° for 5 minutes prior to separation on SDS-PAGE gels under both reducing and
non-reducing conditions.
Heavy and light chains served as the loading controls for the IP experiments.

Gelatin zymography
Bone marrow stromal cell supernatants were collected following 100μM etoposide
treatment in serum free α-MEM. Supernatants were concentrated 10x using Amicon Ultra-15
centrifugal filters (Millipore, Billerica, MA) spun at 3,000g for 95, 30 and 10 minutes,
respectively at room temperature. For gelatinolytic analysis with cell lysates, cell pellets were
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lysed in CCLB without NaVO3, NaF, EDTA and DTT. Following quantitation of supernatant
and cell lysate protein by the BCA protein assay, samples were resolved in 10% SDS-PAGE gels
containing 1% gelatin (Sigma) under non-reducing conditions. Following electrophoresis, gels
were incubated for 30 minutes in 2.5% Triton-X-100 (Mallinckrodt, Inc., Paris, KY) and
subsequently incubated overnight at 37 °C in 1X developing buffer (1.2% Tris Base, 6.3% Tris
HCl, 11.7% NaCl, .7% CaCl, .2% Brij 35). Gels were then stained with 0.5% Coomassie Blue R250 (Bio-Rad Laboratories, Richmond, CA) for 30 minutes at room temperature and then
destained (50% Methanol, 10% acetic acid, 40% dH20) until clear bands were detected,
indicative of active MMP-2.

Detection of intracellular ROS by flow cytometry
Detection of intracellular ROS generation by flow cytometry was performed as
previously described [28]. Briefly, confluent stromal cells were pretreated with 10μM carboxylH2DCF-DA (Molecular Probes, Eugene, OR) for 30 minutes followed by etoposide exposure for
various time points. Nonfluorescent carboxyl-H2DCF-DA was hydrolyzed to H2DCF, which is
oxidized in the presence of H2O2 and emits fluorescence detected in the FL1-H channel. Cells
were trypsinized, rinsed with PBS buffer and immediately run on a BD Biosciences FACScan.
Data were analyzed and processed with CellQuest Pro software (Becton Dickson).

Confocal microscopy
Stromal cells were cultured on coverslips and exposed to etoposide for 30 minutes to 6
hours. After fixation with Methanol/Acetone (1:1) for 30 minutes at room temperature, stromal
cells were incubated with 3μg/100μL anti-phospho-Smad3 antibody or isotype control antibody
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for 3 hours. Following 3 washes with autoclaved PBS, cells were incubated with goat anti-rabbit
IgG-FITC (Southern Biotechnology Associates, Birmingham, AL) for 1 hour. Propidium iodide
(PI, 5 μg/100μL) was used to counterstain the nuclei. Coverslips were mounted onto slides with
Fluormount-B (Fisher Scientific, Orangeburg, NY) and evaluated by confocal microscopy (Carl
Zeiss LSM510).

Pro-B cell adhesion assays
Stromal cells were plated in 96-well plates and exposed to 0-5ng/mL rhTGF-β1 for 72
hours. Cells were thoroughly rinsed with fresh medium 3 times prior to establishment of C1.92
pro-B/stromal cell co-culture. Prior to co-culture, C1.92 pro-B cells were labeled with the
fluorescence dye PKH-26 (Sigma) for 3 minutes and then washed with medium. 5 x105 C1.92
cells were co-cultured with stromal cells for an additional 2 hours. Non-adherent C1.92 cells
were removed by three PBS rinses. 96-well plates were then analyed on a multi-well fluorimetric
reader (CytoFluor, PerSeptive Biosystems) to quantitate fluorescence as a measure of stromal
cell-bound C1.92 cells. Stromal cells alone were included to determine any background
fluorescence.

Pro-B cell proliferation assay
The effect of TGF-β1 on the ability of murine S10 or human-derived stromal cells to
support pro-B cell proliferation was investigated by exposing 100% confluent stromal cell layers
to increasing doses of rhTGF-β1 ( 0-5ng/mL) for 72 hours in 96 well plates.

Following

exposure of stroma to TGF-β1 in vitro, stromal cells were thoroughly rinsed from culture, and
5x105 pro-B cells/mL were added to each well in fresh α-MEM. The proliferative response of
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pro-B cell clone C1.92 to murine stromal cell line S10 has been well characterized [24],
therefore, this combination of cells is particularly informative in determining the effect of TGFβ1 on the ability of stromal cells to support pro-B cell expansion. 25U/mL recombinant murine
IL-7 (Biosource, Camarillo, CA) was included as the established primary proliferative signal for
C1.92 in all samples. Wells were pulsed with 1Ci 3H-TdR 16 hours after the addition of C1.92,
and harvested onto glass wool fiber strips 6 hours later. Incorporated radioactivity was
determined by liquid scintillation counting (LKB/Wallac Model 1410, Gaithersburg, MD) in an
aqueous fluor (Biosafe-II; Research Products International, Mount Prospect, IL). Control wells
of untreated stroma were included in each experiment.

Statistical analysis
Data presented were expressed as mean +/- SEM for triplicate samples. Statistic
significance was determined using the Student’s t-test. P values less than 0.05 were considered
significant.
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RESULTS

Chemotherapy activates Smad3 through phosphorylation at serines 433/435 in human bone
marrow derived stromal cells.
To investigate the phosphorylation of Smad3 in stromal cells following chemotherapeutic
stimulation, stromal cells were treated either for different times, or with various concentrations
of etoposide. Exposure of stromal cells to etoposide resulted in phosphorylation of Smad3 at
serines 433/435 in a time-(Fig 1A) and dose (Fig 1B) dependent manner. Etoposide induced a
rapid elevation of phospho-Smad3 signal as early as 30 minutes which was sustained for
approximately 6~7 hours (Fig 1A). Following the transient increase, phospho-Smad3 levels
diminished for up to 24 hours in the presence of chemotherapy. Etoposide, melphalan,
vincristine, daunorubicin, doxorubicin, 4-hydroperocyclophosphomide and ara-C induced Smad3
phosphorylation in stromal cells to varying degrees (Fig 3C). Treatment of stromal cells with
recombinant TGF-β1 served as a positive control and induced the most pronounced
phosphorylation of Smad3. Total Smad3 protein remained unchanged and served as the lane
loading control throughout the experiments.

Chemotherapy-induced Smad3 phosphorylation is mediated by TGF-β1.
To investigate the potential involvement of TGF-β1 in phosphorylation of Smad3 of bone
marrow stromal cells during chemotherapy, HS-27A stromal cells were exposed to etoposide for
different times or at various concentrations. Quantitative analysis of TGF-β1 by ELISA was
performed using the cell supernatants following treatment. To better distinguish the free (active)
and latent (total) TGF-β1 that may be released, non-acidification and acidification of the stromal
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supernatants were simultaneously utilized prior to assay as described. Exposure of stromal cells
to chemotherapy resulted in elevated TGF-β1 release from stromal cells both in a time- and dose
dependent manner (Fig 2A). Chemotherapy rapidly induced the release of active and latent forms
of TGF-β1 from stromal cell extracellular matrix. In our stromal cell model, active TGF-β1
constituted approximately 5-9% of the total TGF-β1 pool during each treatment phase.
Activation of TGF-β1 preceded phosphorylation of Smad3 with initial increases rapidly
following etoposide treatment for 15 minutes and further elevated at 1 hour. Activation of TGFβ1 in stromal cells appeared to be a transient event, as longer than 1 hour exposure of stromal
cells to chemotherapy correlated with gradual regression of active and total TGF-β1 to the
baseline level.
Immunoprecipitation of TGF-β1 from the stromal cell supernatants indicated that baseline
TGF-β1 in untreated stromal cell supernatants was negligible, with increased TGF-β1
immunoprecipitated from etoposide treated stromal cell supernatants in a dose dependent fashion
(Fig 2B).
Because the anti-TGF-β1 antibody we used for immunoprecipitation of TGF-β1 may
recognize both active and latent form of TGF-β1, we performed additional immunoprecipitation
experiments with antibodies recognizing the free and total TGF-β1(i.e. anti-TGF-β1), the small
latent complex (i.e. anti-LAP/TGF-β1), or the large latent complex (anti-LTBP-1/TGF-β1) to
further address this issue. As shown in Fig 2C, under non-reducing electrophoretic condition, the
major forms of TGF-β1 activated via etoposide treatment are 230 kD and 195 kD large latency
complexes (i.e. LTBP-1/LAP/TGF-β1) as immunoprecipitated by anti-TGF-β1, anti-LAP/TGFβ1 and anti-LTBP-1/TGF-β1 antibodies. In addition, a 100 kD band which represents the small
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latency complex (i.e. LAP/TGF-β1) and a 75 kD LAP band were also detected in etoposidetreated samples. When the same samples were electrophoresed under reducing conditions, the
high molecular weight large and small latency complexes were almost dissociated and two bands
of molecular size of 195 kD (LTBP-1/LAP- TGF-β1) and 25 kD (TGF-β1) were observed.

Disruption of the availability of TGF-β1 blocks the signal transduction initiated by
chemotherapy.
To better understand the role of TGF-β1 in mediating chemotherapy-triggered signals
during bone marrow damage, marrow-derived stromal cells were treated with chemotherapeutic
agents in the presence or absence of anti-TGF-β1 neutralizing antibody. Etoposide, Melphalan
and 4-HC promoted phosphorylation of Smad3 when cells were pretreated with the isotype
control antibody, while phosphorylation of Smad3 was diminished in the presence of TGF-β1
neutralizing antibody (Fig 3A).
This prompted us to more specifically test whether chemotherapy-induced effects on marrow
stromal cells could be disrupted through downregulation of TGF-β1 expression. Human HS-27A
and P148 stromal cells were transiently transfected with TGF-β1 knockdown siRNA prior to
exposure to etoposide. TGF-β1 targeting siRNA transfection diminished the amount of total
TGF-β1 release induced by etoposide treatment in a concentration dependent manner compared
to control dsRNA transfection (Fig 3B, upper panel). Complete loss of TGF-β1 release occurred
when stromal cells were exposed to 150 nM siRNA in the presence of chemotherapy. Consistent
with the diminished availability of TGF-β1 presented in the supernatants, phosphorylation of
Smad3 was also reduced following transfection of stromal cells with various concentrations of
TGF-β1 siRNA during chemotherapy (Fig 3B, lower panel).
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Chemotherapy-induced MMP-2 activity is required for activation of latent TGF-β1.
Gelatin zymography revealed that MMP-2 activity was elevated in S10 stromal cell
supernatants following etoposide exposure as early as 5 minutes, and increased further at 30-60
minutes (Fig 4A). Inhibition of MMP-2 activity by OA-Hy diminished phosphorylation of
Smad3 following etoposide treatment of stromal cells (Fig 4B). To determine whether MMP-2
was required for bone marrow stromal cell activation of TGF-β1, we established stromal cells
from MMP-2-/- knockout mice. Etoposide, Melphalan or 4-HC exposure induced Smad3
phosphorylation in murine MMP-2+/+ stromal cells, while phospho-Smad3 signals were less
pronounced in MMP-2-/- stromal cells (Fig 4C). Addition of active MMP-2 partially restored
treatment-induced

phospho-Smad3 signals in MMP-2-/- cells, and further increased

phosphorylation of Smad3 in MMP-2+/+ stromal cells treated with etoposide (Fig 4D).
To further investigate the role of MMP-2 in mediating activation of TGF-β1 in marrow
stromal cells during chemotherapy, S-10 murine stromal cells transfected with a human MMP-2
construct or vector control were established. Stromal cell clones with comparable expression of
the neomycin resistance gene, NPT II, were selected for further experiments. As shown in Fig
4E, while no substantial differences were observed between S-10 parental and SV-2 vector
transfected cells in terms of activation of Smad3 and MMP-2 during treatment, overexpression of
MMP-2 in SM-8 stromal cells increased baseline and etoposide-induced Smad3 phsophorylation.

Activation of latent MMP-2 by chemotherapy requires the generation of reactive oxygen
species.
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Because MMP-2 exists largely as a latent form in stromal cell matrix, we next sought to
explore the mechanism underlying the activation of pro-MMP-2 during etoposide chemotherapy.
Reactive oxygen species (ROS) was generated following etoposide treatment and was required
for conversion of pro-MMP-2 to its active form. Etoposide rapidly induced production of
intracellular ROS in HS-27A stromal cells as early as 5 minutes following etoposide exposure,
which preceded activation of MMP-2 and TGF-β1 (Fig 5A, upper panel).
Comparable to the activation of MMP-2 and TGF-β1, ROS generation is also a transient
event during chemotherapy in our stromal cell model. The mean fluorescence intensity (MFI)
emitted by oxidized DCF in etoposide treated stromal cells was increased greater than 2-3 fold in
all lines evaluated when compared to untreated controls. Uniquely, ara-C did not stimulate
stromal cell production of H2O2 during short-term (1 hour) chemotherapy (Fig 5A, lower panel).
Reduction of intracellular ROS accumulation with the hydroxyl radical scavenger, N-acetyl
cysteine (NAC), reduced phospho-Smad3 in stromal cells treated with etoposide (Fig 5B).
To confirm the role of ROS in activation of MMP-2, pro-MMP-2 was activated in vitro by
hydrogen peroxide. As shown in Fig 5C, treatment of HS-27A stromal cells with in vitro
activated MMP-2 induced phosphorylation of Smad3 in a dose dependent manner. Because
inhibition of extracellular MMP-2 activity and reduction of intracellular ROS both disrupted
etoposide-induced Smad3 phosphorylation, we sought to determine which one was the initiating
factor in modulating TGF-β1/Smad3 signaling. Hydrogen peroxide induced phosphorylation of
Smad3 only occurred in MMP-2 +/+ but not MMP-2-/- cells, whereas in the presence of pro-MMP2, oxidative stress led to phosphorylation of Smad3 in MMP-2-/- cells (Fig 5D).

P38 mediates etoposide-induced Smad3 phosphorylation in bone marrow stromal cells.
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Smad3 was not directly phosphorylated by TGF-β1 receptor I in a classic fashion, but
appeared to be regulated by p38 MAP kinase in this specific setting. As indicated in Fig 6A, all
the chemotherapeutic drugs evaluated in this study activated p38 kinase. Chemotherapy induced
phosphorylation and activation of both Erk1/2 and p38 kinases in HS-27A cells (Fig 6B),
however, inhibition of Erk1/2 MAPK with U0126 did not result in diminished phosphorylation
of Smad3. In contrast, interruption of p38 kinase activity with SB220025 blocked etoposidetriggered Smad3 phosphorylation. JNK/SAPK was not involved in chemotherapy induced
activation of TGF-β1 signaling in bone marrow stromal cells.

Etoposide treatment results in redistribution of phosphorylated Smad3 protein in human
stromal cells
Changes in cellular distribution of Smad3 protein following etoposide-induced
phosphorylation were evaluated (Fig 7). The phospho-Smad3 signal was negligible in untreated
stromal cells, with only the PI-counterstained cell nuclei clearly detected. Cytoplasmic Smad3
was rapidly phosphorylated in response to etoposide stimulation as early as 30 minutes. Longer
exposure of stromal cells to etoposide induced a gradual redistribution and accumulation of
Smad3 protein in nucleus. After approximately 4 hours of etoposide treatment, the majority of
phospho-Smad3 had translocated into the stromal cell nuclei.

Recombinant TGF-β1 activates Smad3 and impairs stromal cells support of pro-B cell
adhesion and proliferation
To characterize the response of stromal cells to TGF-β1 exposure, human primary P156
stromal cells were treated with rhTGF-β1 (Fig 8A). TGF-β1 rapidly induced phosphorylation of
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Smad3 in P156 stromal cells in a time dependent manner with elevated Smad3 phosphorylaton as
early as 30 minutes and decreased phospho-Smad3 signals thereafter (Fig 8A upper panel). In
contrast to the Smad3 activation pattern induced by chemotherapy, rhTGF-β1 treatment resulted
in the most pronounced Smad3 phosphorylation at 1 and 5ng/mL of TGF-β1, however, 10 and
20ng/mL, resulted in diminished phospho-Smad3 signals (Fig 8A lower panel).
To explore the functional consequences of activation of TGF-β1/Smad3 signaling during
bone marrow damage, bone marrow stromal cells were treated with rhTGF-β1 followed by coculture with C1.92 hematopoietic stem cells. Stromal cells pretreated with TGF-β1 diminished
the ability to support C1.92 cell adhesion to the stromal cell layer (Fig 8B). In addition to
diminished adhesion of the pro-B cells, C1.92 cells co-cultured on TGF-β1 pretreated human or
murine stromal cells had lower cell proliferation (Fig 8C) compared to those on control stromal
cells.
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DISCUSSION

BMT/HSCT has proven an effective treatment for many malignancies that are refractory
to less aggressive approaches [29-32]. Preparative regimens require that pretreatment achieves
maximal killing of tumor cells in peripheral blood and bone marrow, and that it establish
adequate space for subsequently transplanted hematopoietic stem and progenitor cells. During
this process, one challenge is maintaining the hematopoietic support capacity of the bone marrow
microenvironment. Complications associated with HSCT include aplastic anemia or pancytopenia, delay of hematopoietic recovery and severe immunosuppression-related infections
[33-35] and secondary myelofibrosis [36-37]. These observations emphasize the challenge of
utilizing high-dose chemotherapy while attempting to maintain function of bone marrow stromal
cell niches that support hematopoietic recovery.
We have previously reported that high-dose etoposide exposure, while not reducing the
viability of bone marrow stromal cells, resulted in a plethora of functional alterations. Etoposidetreated stromal cells have diminished surface VCAM-1 protein [22] and reduced ability to
support chemotaxis of CXCR4 positive progenitor cells [38]. In addition, stromal cell- and IL-7
dependent pro-B cells grown on etoposide pre-treated stromal cells accumulate in G0/G1 phase of
the cell cycle and subsequently initiate apoptosis [22]. These observations suggest a variety of
treatment-induced stromal cell alterations that potentially influence hematopoietic support
capacity.
Because TGF-β1 has a variety of direct inhibitory effects on hematopoietic cells, we
hypothesized that etoposide induced disruption of bone marrow stromal cell support of pro-B
cells may result, in part, from activation of TGF-β1. Initial studies indicated that bone marrow
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stromal cells responded to chemotherapeutic exposure with downstream phosphorylation of
Smad3. Etoposide treatment rapidly resulted in a dose- and time dependent phosphorylation of
Smad3 protein in bone marrow stromal cells (Fig 1 A, B). The response of stromal cells to a
variety of drugs, including our model drug etoposide, was similar to that induced by rh-TGF-β1
treatment alone (Fig 1C). These data suggested an intracellular signal transducer of TGF-β1 was
activated in response to chemotherapy, and provided indirect evidence that TGF-β1 may be
involved in chemotherapy-induced stromal cell alterations. It should be noted that although
higher doses of etoposide induced stronger phospho-Smad3 signals, longer exposure of stromal
cells to 100 μM etoposide for up to 24 hours did not lead to sustained Smad3 phosphorylation.
Several mechanisms may underlie the transient phosphorylation of Smad3. It is generally
recognized that the protein phosphatases, specifically protein phosphatase 2A, are activated
following stress in a number of cell models [39]. Elevated PP2A activity may subsequently result
in dephosphorylation of signaling molecules, such as Smad3, in stromal cells treated with
etoposide. However, sustained phosphorylation of Smad3 may not be required to elicit a
significant effect. Transit of Smad3 to the nucleus following phosphorylation provides the
potential for diverse changes in expression of Smad3 responsive genes and subsequent alteration
of stromal cell function.
Because R-Smads can also be phosphorylated/activated in response to other members of
the TGF-β1 superfamily [7], we performed several experiments using chemical and genetic
approaches to verify that TGF-β1 is specifically involved in chemotherapy-induced Smad3
phosphorylation (Fig 2 and 3). Treatment of stromal cells with chemotherapy resulted in the
release of active and total TGF-β1 in the supernatants. The free/active form TGF-β1 only
accounts for approximately 5-9% of the total TGF-β1 pool released from chemotherapy-treated
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stromal cells. However, MMP-2 may cleave and release LAP from extracellular matrix and
subsequently release TGF-β1 from LAP or LTBP-1 complexes [40,41]. Therefore it can be
postulated that TGF-β1 activated through chemotherapy may exert its biological functions in an
extended-release manner influenced at multiple regulatory levels by MMP-2.
Central to our model is the role of MMP-2 in activation of latent TGF-β1 in
chemotherapy-treated stromal cells. We have previously determined that bone marrow stromal
cells used in our model predominantly express high levels of MMP-2 (data not shown). In the
current study we demonstrated that MMP-2 acted as an activator of TGF-β1 in human bone
marrow stromal cells and was required for optimal Smad3 phosphorylation following etoposide
exposure. The rationale for focusing on MMP-2 was based on the observation that MMP-2 is
secreted into ECM in association with remodeling during tissue injury and repair [42, 43], and
our own data which indicated that MMP-2 activity is rapidly elevated following etoposide
treatment (Fig 4A). MMP-2 activation paralleled phosphorylation of Smad3, occurring as early
as 5 minutes following treatment. Inhibition of MMP-2 activity with OA-Hy diminished
chemotherapy-induced phospho-Smad3 signals in stromal cells (Fig 4B). These data suggested a
critical role of MMP-2 in converting ECM-bound latent TGF-β1 into its active form. Evaluation
of MMP-2 knockout derived stroma indicated a critical role for MMP-2 during activation of
chemotherapy-induced TGF-β1/Smad3 signaling in bone marrow stromal cells (Fig 4C and 4D).
Transfection of human MMP-2 into murine stromal cells further suggest that MMP-2 plays a
pivotal role in chemotherapy-induced activation of TGF-β1 in our model (Fig 4E). Upregulation
of MMP-2 and MMP-9 expression following TGF-β1 stimulation in several cell types has been
well-documented [44-47]. Thus, the current finding suggests there is potentially a regulatory
feedback loop in the bone marrow matrix during chemotherapeutic stress.
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Evidence suggests that generation of ROS can serve as a secondary message to initiate
signal transduction, in addition to its role in mediating apoptosis [48, 49]. In our model, we
found that following chemotherapeutic stimulation, ROS was rapidly generated in bone marrow
stromal cells (Fig 5A). The drugs that induced phosphorylation of Smad3 were those that also
induced ROS generation. Reduction of intracellular ROS by NAC reduced the phospho-Smad3
level induced by etoposide (Fig 5B).
These data suggest a connection between ROS and MMP-2 activity when combined with
the evidence that in vitro activation of pro-MMP-2 by hydrogen peroxide induced a dose
dependent phosphorylation of stromal cell Smad3 (Fig 5C). The connection is strengthened by
the observation that ROS activation of TGF-β1 is dependent on the presence of MMP-2 (Fig
5D). In contrast to a recent report in which latent TGF-β1 could be directly activated by
asbestos-derived ROS in A549 and mink pulmonary epithelial cells [50], our data indicate that
dependence of TGF-β1 activation on MMP-2 cannot be circumvented during chemotherapeutic
stress in marrow stromal cells. Consistent with the reports [51, 52] in which MMP-2 was
activated by ROS in other cell models, our results suggest that generation of reactive oxygen
species is an early event that initiates the TGF-β1 signaling pathway in bone marrow stromal
cells during chemotherapy. Of note, Ara-C exposure induced phosphorylation of Smad3 in
stromal cells, but did not promote intracellular ROS production. This suggests that other
mechanisms are responsible for activation of Smad3 during Ara-C treatment.
C-terminal phosphorylation by the type I receptor is considered a key event in Smad
activation [7], however, there is evidence indicating other kinase pathways may also regulate
Smad signaling [53, 54]. In our stromal cell model, P38, but not Erk1/2 or JNK, modulated
Smad3 phosphorylation following etoposide treatment (Fig 6B). This indicates p38 may serve as

113

a signal transducer that is downstream of TGF-β1/receptor ligation and directly mediates
phosphorylation of Smad3. Phosphorylation of Smad3 by TGFR I in its C-terminus, or by p38 in
its joint region [55], may initiate distinct signaling and induce different biological consequences.
Translocation of Smad3 from the cytoplasm into the nucleus of stromal cells treated with
etoposide is the hallmark of activation of TGF-β1 signaling (Fig 7). As a transcriptional
regulator, nuclear Smads target a variety of genes [6, 7, 20]. Interestingly, a recent report
documented that TGF-β1 stimulation led to downregulation of SDF-1 expression in bone marrow
MS-5 stromal cells although it was not investigated whether this was a Smad3-dependent effect
[56]. It has also been shown that TGF-β1 treated stromal cells have less cell surface VCAM-1
expression [57]. These reports are consistent with our earlier findings that etoposide treated
stromal cells have diminished chemotactic support [22] and impaired VCAM-1 expression [38]
and our recent data indicating these same cells, when treated rhTGF-β1, have impaired support
of pro-B cell adhesion and proliferation (Fig 8 B&C).
Our current model suggests that dose-escalated chemotherapy may initiate a ROS/MMP2 dependent activation of TGF-β1, which may have direct influence on hematopoietic cells as
well as effects on stromal cell gene expression. Further investigation of these chemotherapyinduced changes may lend insight into strategies to protect the hematopoietic microenvironment
during treatment in an effect to enhance hematopoietic recovery. Of note, very distinct pathways
may be initiated during the acute and chronic phases of the stress response. Consequently,
conclusions regarding the effects of chemotherapy exposure must be interpreted within the
appropriate context as we attempt to better understand the dynamic response of the bone marrow
to chemotherapy.
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FIGURE LEGENDS

Figure 1. Chemotherapy activates Smad3 through phosphorylation at serines 433/435 in human
bone marrow derived stromal cells. Western blot analyses of HS-27A stromal cells treated with
(A) 100μM etoposide for the indicated time points, (B) various concentrations of etoposide for 1
hour, or (C) 3ng/mL TGF-β1, 100µM etoposide, 200 µg/mL melphalan, 20µg/mL vincristine,
100µg/mL daunorubicin, 100µM doxorubicin, 100µg/mL 4-hydroperoxylcyclophosphamide or
100 µg/mL Ara-C for 1 hour. Membranes were probed with anti-phospho-Smad3 (P-Smad3,
ser433/435) then stripped and re-probed with total Smad3 (T-Smad3) specific antibodies.

Figure 2. Chemotherapy-induced Smad3 phosphorylation is mediated by TGF-β1. (A)
Quantitative analysis of the release of active and total TGF-β1 from HS-27A stromal cell
supernatants exposed to etoposide at 0-100μM for 1 hour (upper graph) or at 100μM for 0-6
hours (lower graph). Bars marked with an (*) or (#) indicate significant differences as compared
to untreated controls (P<0.05). (B) Immunoprecipitation of human TGF-β1 from HS-27A and
P148 supernatants following exposure of stromal cells to the indicated concentrations of
etoposide for 1 hour. Supernatants were immunoprecipitated with anti-TGF-β1 and run under
reducing conditions. Western blots were probed with anti-TGF-β1 antibody. Recombinant
human TGF-β1 served as the molecular size control. (C) Immunoprecipitation of TGF-β1 from
HS-27A cell supernatants pre-incubated with 3µg of anti-TGF-β1, anti-LAP/TGF-β1, or antiLTBP-1/TGF-β1 antibodies followed by exposure to 100 μM etoposide for 1 hour. Samples were
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run under both reducing and non-reducing conditions and Western blots probed with anti-human
TGF-β1 antibody.
Figure 3. Disruption of the availability of TGF-β1 blocks the signal transduction initiated by
chemotherapy.

(A) Western blot analysis of HS-27A stromal cells treated with 100µM

etoposide, 200 µg/mL melphalan or 100µg/mL 4-HC for 1 hour. (B) ELISA of released total
TGF-β1 from HS-27A and P148 stromal cells transfected with the indicated concentrations of
TGF-β1 knockdown siRNA or control dsRNA for 48 hours followed by exposure to 100μM
etoposide for 1 hour (upper panel). Bars marked with an (*) or (#) indicated significant
differences as compared to control dsRNA transfections (P<0.05). Western blot analysis of
Smad-3 phosphorylation using the same TGF-β1 siRNA transfection cell lysates is shown in the
lower panel.

Figure 4. Chemotherapy-induced MMP-2 activity is required for activation of latent TGF-1. (A)
Gelatin zymography analysis of supernatants from S-10 stromal cells treated with 100µM
etoposide for 0-6 hours. (B) Western blot analysis of HS-27A and Ped604 stromal cells treated
with 1µM MMP-2 inhibitor OA-Hy for 30 minutes prior to exposure to 100µM etoposide for 1
hour. (C) Western blot analysis of murine C57BL/6 MMP-2 knockout stromal cells (MMP-2-/-,
KO) or wild-type stromal cells (MMP-2+/+, WT) treated with 100µM etoposide, 200µg/mL
melphalan or 100µg/mL 4-HC for 1 hour. (D) Western blot analysis of MMP-2+/+ and MMP-2/- stromal cells treated with 100µM etoposide in the presence or absence of 250 ng/mL
recombinant human active MMP-2 for 1 hour. Untreated controls were not exposed to either
recombinant MMP-2 or etoposide. (E) Gelatinolytic analysis of supernatants and cell lysates
from S-10 parental, vector or MMP-2 transfected S-10 stromal cells treated with 100µM
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etoposide for 1 hour and Western blot analysis of Smad3 phosphorylation and NPT II expression
using the same transfection samples.

Figure 5. Activation of latent MMP-2 by chemotherapy requires the generation of reactive
oxygen species (ROS). (A) Flow cytometric analysis of intracellular ROS in HS-27A stromal
cells treated with 100µM etoposide for 0-4 hour (upper panel) or HS-27A stromal cells treated
with the indicated chemotherapeutic agents identical to those shown in Fig 1C for 1 hour (lower
panel). Untreated control stromal cells in the lower panel are indicated by the solid histogram.
Ara-C treated stromal cell ROS overlays the untreated control histogram. (B) Western blot
analysis of HS-27A or P148 stromal cells pretreated with 20 mM N-acetyl cysteine (NAC)
overnight prior to exposure to 100µM etoposide for 1 hour. (C) Western blot analysis of HS-27A
stromal cells treated with recombinant pro-MMP-2 that was activated in vitro. Cells were
exposed to 0 to 500ng/ml activated MMP-2 for 1 hour. (D) Western blot analysis of MMP-2+/+
and MMP-2-/- stromal cells treated with 10µM H2O2 in the presence or absence of 250ng/mL
pro-MMP-2 for 1 hour.

Figure 6. P38, but not Erk1/2 or JNK kinase, is involved in mediating etoposide-induced Smad3
phosphorylation. (A) Western blot analysis of HS-27A stromal cells treated with TGF-β1 or the
same chemotherapeutic agents shown in Figs 1C and Fig5A (lower panel). (B) Western blot
analysis of HS-27 stromal cells pretreated with vehicle, 10µM Erk1/2 kinase inhibitor U0126,
20µM p38 kinase inhibitor SB220025 or 5µM JNK/SAPK inhibitor SP600125 followed by
etoposide exposure for 1 hour. Blot was stripped and re-probed with antibodies specific for the
proteins indicated.
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Figure 7. Etoposide treatment results in phosphorylation and subsequent nuclear localization of
Smad3 protein in human stromal cells. Double-channel confocal microscopy analysis of HS-27A
stromal cells treated with 100µM etoposide for up to 6 hours. Cells were double-stained with
5µg/100µL PI (Rhodamine, red signal) and 3µg/100µL of anti-phospho-Smad3 antibody
followed by staining with FITC-conjugated anti-rabbit IgG secondary antibody (green signal).
Panels on the right represent merged images of cytosolic and nuclear phospho-smad3 staining.
Original magnifications 200X.

Figure 8. Recombinant TGF-β1 activates Smad3 and impairs stromal cells support of pro-B cell
adhesion and proliferation. (A) Western blot analysis of Smad3 phosphorylation of HS-27A
stromal cells treated with 3ng/mL rhTGF-β1 for the indication time points or the indicated
concentrations of rhTGF-β1 for 24 hours. (B) Adhesion of C1.92 pro-B cells labeled with PKH26 and co-cultured on P156 and S-10 stromal cells pretreated with the indicated concentrations
of rhTGF-β1 for 72 hour. Bars marked with an (*) or (#) indicate significant differences as
compared to untreated controls (P<0.05). (C) 3H-thymidine incorporation of C1.92 pro-B cells
co-cultured on P156 and S-10 stromal cells pretreated with the indicated concentrations of
rhTGF-β1 for 72 hour. Bars marked with an (*) or (#) indicate significant differences as
compared to untreated controls (P<0.05).

Figure 9. Proposed model for activation of the TGF-β1/p38/Smad3 signaling cascade in bone
marrow stromal cells during chemotherapy. Following chemotherapy, stromal cell mitochondria
generate intracellular ROS, which translocates into the extracellular matrix and oxidizes pro-
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MMP-2 complexes. Active MMP-2 subsequently cleaves and releases TGF-β1 from LTBP,
allowing TGF-β1 to bind to its receptor, and initiates phosphorylation of stromal cell p38 kinase.
P38 mediates phosphorylation of Smad3 protein, which can subsequently dimerize with Smad4
and translocates into the nuclei to regulate a diverse set of target genes that may influence
stromal cell support of hematopoietic cell development.
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Figure 1. Chemotherapy activates Smad3 through phosphorylation at serines 433/435 in human
bone marrow derived stromal cells.
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Figure 2. Chemotherapy-induced Smad3 phosphorylation is mediated by TGF-β1.
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Figure 3. Disruption of the availability of TGF-β1 blocks the signal transduction initiated by
chemotherapy.
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Figure 4. Chemotherapy-induced MMP-2 activity is required for activation of latent TGF-1.
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Figure 5. Activation of latent MMP-2 by chemotherapy requires the generation of reactive
oxygen species (ROS).
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Figure 6. P38, but not Erk1/2 or JNK kinase, is involved in mediating etoposide-induced Smad3
phosphorylation.
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Figure 7. Etoposide treatment results in phosphorylation and subsequent nuclear localization of
Smad3 protein in human stromal cells.
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Figure 8. Recombinant TGF-β1 activates Smad3 and impairs stromal cells support of pro-B cell
adhesion and proliferation.
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Figure 9. Proposed model for activation of the TGF-β1/p38/Smad3 signaling cascade in bone
marrow stromal cells during chemotherapy.
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ABSTRACT

Bone marrow stromal cell function is a critical influence on hematopoietic reconstitution
following progenitor or stem cell transplantation.

Stromal cells support hematopoietic cell

migration, survival, and proliferation. We have previously reported that stromal cell MMP-2 is
necessary for optimal support of pro-B cell chemotaxis through its regulation of SDF-1 release.
Following exposure to the topoisomerase II inhibitor, etoposide, stromal cell MMP-2 protein
expression is reduced. This reduction is not correlated with diminished mRNA expression,
increased intracellular accumulation, or altered stability of MMP-2 protein. Based on these
earlier observations, the current study investigated the mechanism by which VP-16 may alter
translation of MMP-2 in bone marrow stromal cells. Rapid dephosphorylation of 4EBP-1,
P70S6K and S6 following VP-16 exposure was observed, consistent with blunted translational
efficiency. We also observed an immediate increase in serine/threonine phosphatase activity in
stromal cells exposed to VP-16, suggesting this may be one mechanism by which the activity of
4EBP-1 and P70S6K, which require phosphorylation for optimal activity, is reduced. Chemical
inhibitors and siRNA specific for the catalytic subunit of PP2A did not block the protein
phosphatase activity associated with dephosphorylation of 4EBP-1 and P70S6K in VP-16 treated
stromal cells. These observations are consistent with disrupted regulation of MMP-2 translation
in stromal cells exposed to VP-16. In addition, these data suggest that one mechanism by which
VP-16 may alter stromal cells of the bone marrow microenvironment is through disrupted
translation of proteins.
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INTRODUCTION

Prior to bone marrow transplantation, myelosuppression or bone marrow ablation is often
achieved by exposure to high doses of chemotherapeutic agents. Hematopoietic reconstitution
following transplantation is supported, in part, by bone marrow stromal cells. We and others
have shown that chemotherapy can blunt stromal cell support of hematopoietic cell proliferation
and survival through disruption of proteins that contribute to this process, including, VCAM-1,
IGF-1 and SDF-1 (1-5).

Inefficient hematopoietic reconstitution may result, in part, from

alteration of the bone marrow microenvironment’s function by chemotherapy.
We have previously reported that following VP-16 exposure, stromal cell matrix
metalloproteinase-2 (MMP-2) protein is reduced (6).

This is functionally significant because

MMP-2 releases heparin-sulfated proteoglycan bound SDF-1 present on stromal cell surfaces
into the extra-cellular matrix (7-10). Subsequently, a chemotactic gradient is established that
supports migration of CXCR4 positive hematopoietic cells. This SDF-1 gradient is necessary for
hematopoitic progenitor cell recruitment to, and retention within, the bone marrow following
transplantation (11;12). In an in vitro model, establishment of the chemotactic gradient was
restored by addition of recombinant MMP-2 to VP-16 exposed stromal cells. MMP-2-/- bone
marrow stromal cell support of chemotaxis of CXCR4 positive cells was also restored by
recombinant MMP-2 (6). Based on the role of MMP-2 in regulating SDF-1 availability in the
bone marrow microenvironment, it is important to better understand the mechanism by which
MMP-2 protein is diminished in stromal cells exposed to VP-16. This study is focused on
regulation of translation due to our earlier observations that diminished stromal cell MMP-2
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protein in VP-16 treated stromal cells was not due to reduced mRNA expression, protein
stability, or altered secretion (6).
MMP-2 mRNA contains both a high degree of secondary structure and a 5’ tract of
pyrimidines (5’TOP). These characteristics are consistent with regulation of expression at the
level of translation (13). One rate-limiting step in regulation of translation of mRNAs with a
high degree of secondary structure is binding of eIF4E to the ribosomal cap. The inhibitor of
eIF4E, 4EBP-1, when dephosphorylated, binds to eIF4E preventing interaction with the
ribosome, resulting in translational repression (14).

Phosphorylated 4EBP-1 interacts less

efficiently with eIF4E allowing it to bind to the ribosome with other members of the 40S preinitiation complex, eIF4A and eIF4G. Subsequently, translation is initiated (15). Exposure of
Swiss 3T3 fibroblasts or MCF-7 breast cancer cells to VP-16 has previously been reported to
diminish 4EBP-1 phosphorylation and increase binding to eIF4E (16;17), resulting in inhibition
of translation of specific mRNAs, including MMP-2.
Another translational regulatory protein, P70S6K, phosphorylates and activates ribosomal
protein S6, which binds to the 40S ribosome and initiates translation of proteins containing a
5’TOP (18;19). VP-16 exposure of 3T3 fibroblasts has been reported by others to decrease
P70S6K activity (16). Therefore, we investigated P70S6K and S6 ribosomal protein activity in
stromal cells exposed to VP-16.

Following VP-16 exposure, we observed diminished

phosphorylation of 4EBP-1, P70S6K, and S6 proteins.

Theses observations are consistent with

disruption of translation.
As a potential influence on phosphorylation status of 4EBP-1 and P70S6K, phosphatase
activity in VP-16 treated bone marrow stromal cells was evaluated. The serine/threonine protein
phosphatase, PP2A has been shown to regulate both 4EBP-1 and P70S6K activity through

141

interaction with mTOR (20;21). mTOR sequesters PP2A rendering the phosphatase inactive.
Upon release from mTOR, PP2A dephosphorylates serine and threonine residues present on both
4EBP-1 and P70S6K which are required for translational activation. Inhibition of mTOR by
rapamycin in bone marrow stromal cells results in diminished MMP-2 protein.

Also, an

increase in serine/threonine phosphatase activity was detected in stromal cells exposed to VP-16.
However, our data suggest that diminished phosphorylation of 4EBP-1 and P70S6K in VP-16
treated stromal cells was not due to increased PP2A activity.
While this study was prompted by the earlier observation of reduced MMP-2 protein
expressed by VP-16 treated stromal cells, the broader goal was to determine if specific
translational regulatory proteins are influenced by commonly used chemotherapy. Our data
suggest that alteration of translational regulation following drug-induced stress may be one
mechanism by which chemotherapy alters the hematopoietic support capacity of the bone
marrow microenvironment.

Understanding the details of signaling pathways initiated by

chemotherapy, distinct from those that drive apoptosis in actively dividing cells, will improve
our ability to modulate damage in cells that would ideally be spared from treatment-induced
damage.
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MATERIALS AND METHODS

Cell lines and culture conditions
P156 and SMD1 stromal cell cultures were initiated from human bone marrow from
consenting donors, with approval by the West Virginia University Institutional Review Board, as
previously described (1). All primary bone marrow stromal cell cultures were initiated from
donors with no previous chemotherapy exposure. Bone marrow stromal cells were maintained in
α-MEM supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 1% L-glutamine
(GIBCO, Grand Island, NY), 1% Penicillin/Streptomycin (Sigma, St. Louis, MO), and 0.1% 2beta-mercapthanol (Sigma, St. Louis, MO). The cloned murine bone marrow stromal cell line
S10 was provided by Dr. Kenneth Dorshkind (University of California Los, Angeles).
Characterization and maintenance of S10 has been previously described in detail (22).

Chemotherapy and other chemical agents
Chemotherapy: Etoposide (VP-16, Bristol Laboratories, Princeton, NJ) was stored at
-20°C at a concentration of 33.98mM and diluted in α-Modification of Eagles Medium (α-MEM,
Gibco, Grand Island, NY) to the indicated concentrations prior to use.
The FRAP/mTOR inhibitor, rapamycin, and the MAP kinase inhibitor, PD98059, were
purchased from Cell Signaling Technology (Beverly, MA). The PP2A inhibitor okadiac acid
(OA) and λ-phosphatase were purchased from Sigma (St. Louis, MO).
Confluent bone marrow stromal cells were pre-treated with 10nM OA for 1 hour prior to
the addition of VP-16 to cultures as indicated. Stromal cell lysates were incubated with the
indicated concentrations of λ-phosphatase for 30 minutes at 30°C in 1x λ protein phosphatase
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buffer (50mM Tris-HCl, pH 7.5, 0.1mM Na2EDTA, 5mM dithiothreitol, and 0.01% BRIJ35) and
2mM MnCl2 and subjected to SDS-PAGE to determine if the mobility of 4EBP-1 correlates with
phosphorylation.

Antibodies and Western blot analysis
Rabbit polyclonal anti-4EBP-1, anti-phospho-S6 (Ser235/236), anti-S6, anti-phosphoP70S6K (Thr389), anti-P70S6K, and mouse monoclonal anti-nonmethylated PP2A/c (4B7) were
purchased from Cell Signaling Technology (Beverly, MA). Mouse monoclonal anti-MMP-2
antibody was purchased from Calbiochem (San Diego, CA), mouse monoclonal anti-GAPDH
from Research Diagnostics Inc., (Flanders, NJ) and polyclonal anti-rabbit β-actin antibody was
purchased from Santa Cruz Technologies (Santa Cruz, CA).
Confluent stromal cells were treated with 25-100μM VP-16 for 1 hour or 100µM VP-16
for 10-180 minutes. Following treatment, stromal cells were lysed in complete cell lysis buffer
(CCLB) (50mM Tris-HCl, pH 7.4, 150mM NaCl, 1% Triton-X-100, 0.25% Na-deoxycholate,
1mM EDTA, and 1mM NaF, 1mM dithiothreitol (DTT), 1mM phenylmethylsulphonylfluoride
(PMSF), 1mM activated Na3VO4, 1µg/mL aprotinin, 1µg/mL leupeptin, and 1µg/mL pepstatin)
on ice for 15 minutes. Following centrifugation at 14,000 rpm for 15 minutes, supernatants were
collected and protein concentration was determined using the bicinchoninic acid (BCA) protein
assay (Pierce, Rockford, IL). Proteins were resolved on SDS-PAGE gels and transferred to
nitrocellulose membranes. Membranes were blocked in TBS/5% nonfat dry milk/0.1% Tween20 at room temperature for 1 hour, probed with the indicated primary antibodies, and washed in
TBS/0.1% Tween-20. Following incubation with horseradish peroxidase-conjugated secondary
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antibodies, signal was visualized with enhanced chemiluminescence reagents (Amersham,
Pharmacia Biotech, Piscataway, NJ).

Serine/Threonine Protein Phosphatase Activity Assay
Stromal cells were exposed to the indicated concentrations of VP-16 for 30-180 minutes
or the indicated concentrations of rapamycin for 1 hour and cells were lysed in low detergent
PP2A Buffer (0.25% Nonidet-P 40, 50mM Tris, pH 7.4, 1mM PMSF, 10µg/mL leupeptin,
10µg/mL aprotinin). 1µg of protein was incubated with 37.5 µg phosphopeptide in reaction
buffer (50mM imidazole, pH 7.2, 0.2% EGTA, 0.02% 2-ME, and 0.1% BSA) for 30 minutes at
30°C as recommended by the manufacturer.

Following incubation, an equal volume of

molybdate dye was added and samples were read on a plate reader at 590nM (Biotek
Instruments, Inc., Winoski, VT) and analyzed by the KC junior software.

PP2A/c siRNA
For transient murine PP2A/c small interfering RNA (siRNA) transfection, Lipofectamine
2000 (Invitrogen, Carlsbad, CA) and 100nM nontargeting double-stranded RNA control or
PP2A/c knockdown siRNA (Dharmacon, Lafayette, CO) were diluted and combined. S10 were
cultured overnight and transfected with 100nM control or PP2A/c siRNA for 24 hours. Seventytwo hours following transfection, S10 was exposed to 100µM VP-16 for 1 hour. Stromal cell
lysates were collected for western blot analyses.

Statistical Analysis
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Stastical analysis was performed using Student’s t-test to detect differences among means
(SigmaStat Version 9.0 software, SPSS Inc., Chicago, IL). All statistical analyses represent
treated samples compared to control levels. Statistically significant differences are indicated by
an asterisk.
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RESULTS

VP-16 disrupts activity of translational regulatory proteins, S6, P70S6K, and 4EBP-1
Both murine S10 (Fig. 1A) and human bone marrow stromal cells (Figure 1B) display
rapid dephosphorylation of 4EBP-1 protein following VP-16 exposure.

To confirm that

increased mobility of 4EBP-1 correlates with diminished phosphorylation, S10 cell lysates
incubated with increasing amounts of lambda phosphatase have three distinct forms of 4EBP-1
labeled α, β, and γ, with β representing the protein with the highest level of phosphorylation and
γ representing unphosphorylated 4EBP-1 (Fig. 1C). Phosphorylation of 4EBP-1 is diminished in
a concentration dependent manner in both S10 (Fig. 1D) and SMD1 stromal cells (Fig. 1E)
exposed to VP-16.
We next evaluated the phosphorylation status of S6 and P70S6K, as an indication of
activity. S10 and SMD1 stromal cells exposed to VP-16 have diminished phosphorylation of S6
ribosomal protein that is time and concentration dependent (Figs. 2A-D). Total S6 protein,
normalized to β-actin, was not influenced by identical treatment. VP-16 treated S10 and P156
stromal cells also had decreased phosphorylation of P70S6K as compared to total P70S6K and
GAPDH which was time and concentration dependent (Figs. 3A-D).

mTOR activity is required for optimal phosphorylation of 4EBP-1 and P70S6K Based on the observation that VP-16 exposure diminished the phosphorylation of P70S6K,
S6, and 4EBP-1 proteins, we next investigated potential upstream regulators that may converge
on these targets. Following exposure to rapamycin for 1 hour, SMD1 and S10 stromal cells were
evaluated for phosphorylation of P70S6K and 4EBP-1. P70S6K phosphorylation is abrogated
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following 10µM rapamycin exposure (Fig. 4A), while 4EBP-1 phosphorylation is reduced (Fig.
4B).

Serine/Threonine protein phosphatase activity is rapidly increased following VP-16 exposure
To determine if VP-16 exposure results in increased phosphatase activity, we evaluated
the activity of serine/threonine phosphatases in S10 and SMD1 stromal cells following exposure
to VP-16.

An increase in serine/threonine phosphatase activity, after 5 minutes of VP-16

exposure, occurred in S10 (Fig. 5A) and SMD1 stromal cells (Fig. 5D). A concentration
dependent increase in serine/threonine activity in stromal cells exposed to increasing
concentrations of VP-16 was also observed (data not shown).

To determine if the

serine/threonine phosphatase PP2A is specifically responsible for dephosphorylation of 4EBP-1
and P70S6K in S10 and SMD1 stromal cells we utilized the PP2A inhibitor okadiac acid (OA) and
siRNA specific for the catalytic site of PP2A.

Inhibition of PP2A with OA did not blunt the

dephosphorylation of 4EBP-1 (Fig. 5B) or P70S6K (Fig. 5C) in stromal cells exposed to VP-16.
In addition, inhibition of PP2A expression by siRNA did not block chemotherapy induced
dephosphorylation of 4EBP-1 (Fig. 5E) or P70S6K (Fig. 5F).

Stromal cells exposed to rapamycin display diminished MMP-2 protein and increased
serine/threonine activity
To determine whether rapamycin effects on P70S6K and 4EBP-1 resulted in a
downstream effect of reduced MMP-2 protein expression, stromal cells were exposed to either
rapamycin, or VP-16 for comparison. Following 6 hours of treatment with either 100µM VP-16,
or 10-500nM rapamycin, S10 (Fig. 6A) and SMD1 (Fig. 6B) display diminished MMP-2 protein
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expression by western blot. Additionally we found elevated serine/threonine phosphatase
activity following exposure to 10 and 100 nM rapamycin in S10 (Fig. 6C) and P156 (Fig. 6D)
stromal cells.
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DISCUSSION

Bone marrow stromal cells have been demonstrated by several groups to be vulnerable to
chemotherapy (1-5), without a loss of viability (1). We and others have identified disruption of
several stromal cell proteins which directly correlate with support of hematopoietc cells. One
example is diminished MMP-2 protein produced by VP-16 treated stromal cells, coincident with
loss of optimal chemotactic support of CXCR4+ hematopoietic cells (6).

In the current study

we investigated potential mechanisms that may underlie diminished MMP-2 protein expression
by evaluating factors which regulate translation.
Translation of proteins in which the RNA contains a high degree of secondary structure is
regulated, in part, by 4EBP-1. When phosphorylated, 4EBP-1 cannot bind to, and inhibit, the
mRNA cap binding protein eIF4E (14). Following VP-16 exposure, phosphorylation of 4EBP-1
in bone marrow stromal cells is diminished (Fig. 1) which correlates with its ability to inhibit
eIF4E, and subsequently translation. In addition to examining phosphorylation of 4EBP-1 by
western blot analysis, confocal microscopy was performed to evaluate the cellular distribution of
4EBP-1 and eIF4E in stromal cells exposed to VP-16. In the presence of VP-16, eIF4E and
4EBP-1 demonstrate co-localization in stromal cells, while in untreated stromal cells 4EBP-1
and eIF4E co-localization is less pronounced (data not shown).

These data demonstrate that

activity of proteins that influence translation are altered in stromal cells exposed to VP-16 as
reflected by changes in phosphorylation status and suggested by cellular localization.
In addition to regulation by 4EBP-1, MMP-2 also contains a 5’TOP. RNA that contains
a 5’TOP is specifically regulated by P70S6K and S6 ribosomal proteins. Both 4EBP-1 and P70S6K
phosphorylation was diminished in stromal cells exposed to VP-16 (Figs. 2 and 3). Both of these
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factors are regulated by mTOR.

mTOR has previously been shown to sequester the

serine/threonine phosphatase PP2A (21). Binding of PP2A to mTOR renders it inactive and
unable to dephosphorylate substrates, including 4EBP-1 and P70S6K (21). Stromal cells exposed
to VP-16 display increased serine/threonine phosphatase activity. However, we were unable to
identify the specific phosphatase (Fig. 5). Studies that are beyond the scope of the current one
will determine the identity of the serine/threonine phosphatase activated in response to VP-16
exposure. Preliminary data utilizing the phosphatase inhibitors OA and fostriecin indicate PP1
is not responsible for dephosphorylation of 4EBP-1 or P70S6K in VP-16 treated stromal cells
(data not shown). Other potential candidates include PP2B or calcineurin which is expressed in
all mammalian cells and, PP5, which is also ubiquitously expressed and displays similar
structure to PP2A (23).
In addition to increased phosphatase activity following VP-16 exposure, we also
investigated altered kinase activity in stromal cells exposed to VP-16 as a potential influence of
activity of translational regulatory proteins.

MAPK proteins have been reported to

phosphorylate and activate 4EBP-1 (24), while the specific kinase for P70S6K phosphorylation is
PDK1 (25). In the current study, the activity, determined by phosphorylation status, of JNK,
p38, ERK, or PDK1 was not altered by VP-16 (data not shown). These data collectively suggest
that phosphatase activity, in contrast to kinase activity, may be the predominant mediator of the
immediate response of bone marrow stromal cells to VP-16 induced stress.
Translation of other stromal proteins that may be influenced by VP-16 include those
known to contain 5’TOPs such as ribosomal proteins and elongation factor 1 alpha and 2 (26;27).
Identification of additional 5’TOP containing mRNAs expressed by stromal cells will lend
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further insight into the pathways by which chemotherapy may alter the bone marrow
microenvironment.
To specifically evaluate the influence of inhibition of the upstream regulatory factor
mTOR, in the absence of the diverse effects of VP-16, we exposed stromal cells to rapamycin.
Following exposure to rapamycin, stromal cells display increased serine/threonine phosphatase
activity, diminished P70S6K and 4EBP-1 phosphorylation, and reduced MMP-2 protein
expression. These rapamycin-induced effects mirror those of VP-16 treatment. Stromal cell Akt
activity was not altered following VP-16 exposure (data not shown), suggesting VP-16 affects a
downstream target.
Our data suggest that stromal cells exposed to VP-16 display diminished translation of
MMP-2 protein, in part, due to altered activity of the translational regulatory proteins 4EBP-1,
S6, and P70S6K. Understanding the mechanism that underlies disrupted synthesis of stromal cell
MMP-2 may serve as a model in which we can investigate chemotherapy induced alterations of
stromal cell function in the bone marrow microenvironment. Of note, these data represent
chemotherapy induced alterations of stromal cells exposed only to VP-16. While VP-16 was the
chemotherapeutic agent most extensively evaluated, translational regulation in stromal cells
exposed to the chemotherapeutic agents melphalan and 4HC was also investigated. Melphalantreated stromal cells display diminished phosphorylation of translational regulatory proteins
4EBP-1 and P70S6K, while exposure to 4HC does not induce alterations in these translational
regulatory proteins.

These observations suggest that chemotherapeutic agents with distinct

modes of action may have specific effects on translation of proteins that subsequently determines
their effect on the functional integrity of the cell.
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FIGURE LEGENDS

Figure 1. Stromal cell 4EBP-1 phosphorylation is diminished following VP-16 exposure. A, S10
and B, SMD1 primary human stromal cells were exposed to 100µM VP-16 for 5-180 minutes
and subjected to western blot analysis for 4EBP-1 phosphorylation and GAPDH evaluation.
Arrows pointing to α, β, and γ forms of protein indicate phosphorylated 4EBP-1, moderately
phosphorylated 4EBP-1, and unphosphorylated 4EBP-1, respecively. C, S10 stromal cell
lysates were treated with up to 1000U of λ-phosphatase for 30 minutes and subjected to western
blot for analysis of 4EBP-1 mobility and GAPDH. D, S10 and E, P156 primary human stromal
cells were evaluated for phosphorylation of 4EBP-1 and GAPDH following exposure to 25100μM VP-16 for 1 hour. Data are representative of three independent experiments.

Figure 2. Phosphorylation of stromal cell S6 protein is diminished following VP-16 exposure. A
and B, S10 or C and D, SMD1 stromal cells were exposed to 100µM VP-16 for 10-180 minutes
or 25-100μM VP-16 for 1 hour. Following exposure, cell lysates were subjected to western blot
for analysis of phosphorylated S6 (P-S6), total S6 (T-S6), and β-actin protein as a lane loading
control. Representative data from three independent experiments are shown.

Figure 3. Phosphorylated P70S6K is diminished in stromal cells following VP-16 exposure. A and
B, S10 and C and D, SMD1 primary human stromal cells were exposed to either 100µM VP-16
for 10-180 minutes or 25-100μM for 1 hour. Following exposure, cell lysates were collected and
subjected to western blot analysis for phosphorylated P70S6K (P-P70S6K), total P70S6K (T-P70S6K),
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and GAPDH. The antibody used in these experiments recognizes both phosphorylated P70S6K
and P85S6K (P-P85S6K).

Figure 4. mTOR activity is required for phosphorylation of P70S6K and 4EBP-1 in stromal cells.
S10 stromal cells were exposed to either 100µM VP-16 or 1.0-250nM concentrations of
rapamycin for 1 hour. Following exposure, cell lysates were collected and subjected to western
blot for analysis of A, P70S6K and GAPDH or B, 4EBP-1 and GAPDH. Data are representative of
three independent experiments.

Figure 5. Serine/threonine phosphatase activity is rapidly increased in stromal cells exposed to
VP-16. A, S10 or D, SMD1 stromal cells were treated with 100µM VP-16 for 10-180 minutes.
Following exposure, stromal cells were lysed, and analyzed for phosphatase activity by a
serine/threonine phosphatase specific activity assay. All samples were evaluated in triplicate.
An * indicates a significant increase in phosphatase activity. B and C, S10 stromal cells were
either left untreated or pre-treated with 10nM of OA for 30 minutes. Following pretreatment,
stromal cells were then exposed to 100μM VP-16 for 1 hour. Cell lysates were collected and
analyzed for expression of B, 4EBP-1 and GAPDH or C, P-P70S6K and GAPDH. E and F, S10
stromal cells were either untreated or transfected with 100nM control or siRNA specific for the
catalytic unit of murine PP2A (PP2A/c) for 24 hours. 72 hours after transfection, S10 stromal
cells were collected and E, PP2A/c, 4EBP-1, and GAPDH protein levels or F, PP2A/c, P70S6K,
and GAPDH were analyzed by western blot. Data are representative of three independent
experiments.
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Figure 6. Stromal cells exposed to rapamycin have diminished MMP-2 protein expression and
increased serine/threonine phosphatase activity. A, S10 or B, SMD1 stromal cells were exposed
to 10-500nM rapamycin or 100µM VP-16 for 6 hours. Following treatment, stromal cells were
collected and evaluated for expression of MMP-2 and GAPDH by western blot. Data are
representative of three independent experiments. C, S10 stromal cells and D, P156 were exposed
to 100µM VP-16 for 1 hour. Following treatment serine/threonine phosphatase activity was
evaluated as pmol of phosphate released from S10 or P156 cells. An * indicates a significant
increase in phosphate activity compared to control.
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Figure 1. Stromal cell 4EBP-1 phosphorylation is diminished following VP-16 exposure.
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Figure 2. Phosphorylation of stromal cell S6 protein is diminished following VP-16 exposure.
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Figure 3. Phosphorylated P70S6K is diminished in stromal cells following VP-16 exposure.
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Figure 4. mTOR activity is required for phosphorylation of P70S6K and 4EBP-1 in stromal cells.

163

Figure 5. Serine/threonine phosphatase activity is rapidly increased in stromal cells exposed to
VP-16.
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Figure 6. Stromal cells exposed to rapamycin have diminished MMP-2 protein expression and
increased serine/threonine phosphatase activity.

165

CHAPTER V

GENERAL DISCUSSION
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The broad goal our studies was to understand chemotherapy-induced alterations of the
bone marrow microenvironment. Specifically, we were interested in understanding mechanisms
by which chemotherapy disrupts bone marrow stromal cell support of hematopoietic cell
chemotaxis and survival.
To evaluate chemotherapy-induced alteration of the bone marrow microenvironment, we
utilized an in vitro co-culture model which includes both primary derived human bone marrow
stromal cells and pro-B cells. While stromal cells provide support to developing hematopoietic
cells of all lineages (1;2), disruption of stromal cell support of B-lymphopoiesis was our main
focus (3;3;4). Therefore, we utilized pro-B cells to evaluate stromal cell function in the presence
and absence of chemotherapy.
The major component of our in vitro model, and the focus of our research, are primary
human derived bone marrow stromal cells. These cells are isolated from consenting donors who
have not been exposed to chemotherapy. Stromal cells were characterized by the ability to
support B-cell hematopoiesis, production of soluble SDF-1 (CXCL-12), and expression of
surface VCAM-1 (5-7). Evaluation of human-derived bone marrow stromal cells is appealing
because it allows for potential extrapolation of our observations to patients, and therefore,
theoretically provides clinical relevance to our model of microenvironment damage. Another
advantage of using primary stromal cell lines is that we were able to analyze a large number of
patient derived stromal cells to determine if stromal cell response to chemotherapy was
consistent. While we have found differences in the magnitudes of primary-derived stromal cell
response to chemotherapy, the trend in response to chemotherapy was consistent. For example,
primary derived stromal cells chronically exposed to chemotherapy display variation in the
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magnitude of MMP-2 reduction, described in Chapter II, however, in all primary cells evaluated
MMP-2 production was diminished.
A main goal of this work was to determine the effects of dose-escalated chemotherapy
used prior to BMT on stromal cell support of hematopoiesis.

Therefore, we evaluated

chemotherapeutic agents used to treat patients prior to receiving a BMT. Etoposide, or VP-16, is
a topoisomerase-II inhibitor which inhibits DNA synthesis by preventing S/G2 cell cycle
transition (8). While VP-16 is the primary focus of many of the studies described in Chapters II,
III, and IV, other chemotherapeutic agents used prior to transplantation were also evaluated.
Both melphalan and cyclophosphamide are alkylating agents whose mechanism of action is to
add alkyl groups to DNA molecules ultimately preventing DNA repair and RNA synthesis (9).
Unlike VP-16 and melphalan, cyclophosphamide is not metabolized in vitro therefore we utilized
the metabolite, 4-hydroperoxycyclophosphamide (4HC), in our in vitro stromal cell studies (10).
Use of these representative chemotherapeutic agents in our in vitro stromal cell experiments
enabled us to gain a better understanding of the direct effects of these agents on stromal cell
function.
It is well documented that chemotherapy, including the agents utilized in these studies,
initiates apoptosis in actively dividing cells (11-14). However, confluent, stromal cells exposed
to chemotherapy do not initiate apoptosis or undergo necrosis.

Studies by Gibson et al.

demonstrated that non-dividing stromal cells exposed to chemotherapy do not initiate apoptosis,
confirmed by DNA laddering experiments and propidium iodide staining (15). Furthermore,
chemotherapy can be removed from stromal cell cultures following treatment, and the stromal
cells will proliferate when re-plated at a sub-confluence (unpublished observations). For these
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reasons we feel confident that the functional alterations of stromal cells exposed to
chemotherapy are not the result of initiation of stromal cell apoptosis.
Establishment of hematopoiesis and recovery of immune function is imperative following
a BMT. It has been documented that full immune system recovery of patients following ablative
chemotherapy and BMT is approximately one year (16). Bone marrow stromal cell function,
measured by CFU-F, in these patients is also disrupted for at least one year (17). In addition to
these published reports, observations of breast cancer patients receiving a preparative regimen
containing VP-16 displayed delayed hematopoietic reconstitution, even in the presence of
exogenous growth factors (unpublished observations).

These observations prompted our

investigation of the mechanisms by which chemotherapy disrupts stromal cell function as a key
regulator of immune reconstitution.
To investigate disrupted stromal cell function, we evaluated proteins produced by stromal
cells which have been previously shown to contribute to hematopoietic support. Gibson et al.
determined that following VP-16 exposure, murine bone marrow stromal cells display
diminished surface VCAM-1 protein (15). Many studies have established a role for VCAM-1 in
normal hematopoietic processes including support of hematopoietic development and
mobilization and engraftment of transplanted progenitors (18-21). Therefore, diminished stromal
cell VCAM-1 expression provides a mechanism by which chemotherapy alters stromal cell
function and may impact hematopoietic reconstitution following BMT. Following this initial
observation of diminished VCAM-1 expression on murine stromal cells, primary human bone
marrow stromal cell lines were also shown to display diminished VCAM-1 expression following
VP-16 expression (5). In order to understand the impact of chemotherapy, specifically VP-16,
on stromal cell VCAM-1 expression, transcription of VCAM-1 was evaluated in the presence of
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VP-16.

Following VP-16 exposure, stromal cells display diminished VCAM-1 mRNA

expression which correlated with reductions in nuclear p65, a component of the VCAM-1
transcription factor, NF-κB (5).
In addition to VCAM-1, we have also established that following VP-16 exposure, SDF-1
protein is diminished in stromal cell supernatants (6). As indicated in Chapter I, SDF-1 function
is essential for hematopoiesis (22), and data presented in Chapter II determined that alterations in
extra-cellular bone marrow stromal cell SDF-1 result in reduced chemotactic support (6).
Chemotherapy-induced reduction of SDF-1 may contribute to disrupted hematopoietic
reconstitution following BMT, due to an inefficient homing of transplanted cells to bone
marrow.
One goal of my work was to identify the mechanism by which extracellular bone marrow
stromal cell SDF- 1 protein was diminished following chemotherapy exposure. SDF-1 mRNA
and intracellular protein expression were not reduced by chemotherapy (6). Therefore, we
investigated SDF-1 release from stromal cell surfaces. MMP-2 is reported to regulate the
availability and activity of proteins present in the extracellular matrix, including those involved
in regulation of hematopoiesis (7;23-26). Following chemotherapy exposure, MMP-2 protein is
diminished in stromal cell supernatants (27). Evidence, summarized in chapter II, suggests that
MMP-2 regulates SDF-1 release from bone marrow stromal cell surfaces. Consistent with that
observation, bone marrow stromal cells isolated from MMP-2-/- mice did not efficiently support
chemotaxis. Relevant to our model, recombinant MMP-2 was capable of restoring VP-16
induced disruption of stromal cell chemotaxis (27). These data suggest that following chronic
exposure to VP-16, MMP-2 levels may represent a marker for recovery of the microenvironment
in patients receiving chemotherapy treatment.
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In addition to the effects of chronic exposure to VP-16, we also evaluated the acute
effects of chemotherapy exposure on stromal cell function. MMP-2 activity is increased in
stromal cells exposed to VP-16 for 30 minutes and sustained for up to 6 hours. The increase in
MMP-2 activity correlated with an increase in reactive oxygen species (ROS), which have been
shown to cleave MMP-2’s pro-domain resulted in activation of the MMP-2 molecule (7;28).
The immediate increase in MMP-2 activity results in activation of TGF-β through release from
LAP and LTBP (7). Pre-treatment of stroma with recombinant TGF-β resulted in diminished
stromal cell support of pro-B cell proliferation and adhesion. These data correlate with other
published observations implicating TGF-β as a negative regulator of hematopoiesis (29-31).
Therefore, activation of TGF-β by MMP-2 may contribute to disrupted stromal cell support of
hematopoiesis following chemotherapy exposure. Furthermore, treatment of stroma with TGF-β
resulted in alterations in stromal cell phenotype which may contribute to re-modeling of the
microenvironment, in addition to the direct effects on stromal cell support of hematopoietic
function.
Our next goal was to identify the mechanism by which MMP-2 protein is diminished in
stromal cells chronically exposed to chemotherapy. MMP-2 mRNA, secretion, and stability
were not altered following chemotherapy exposure. These observations, in conjunction with the
previously published reports indicating MMP-2 mRNA contains elements which allow for
translational regulation, prompted our investigation of MMP-2 translation during chemotherapy
exposure.

The eukaryotic initiation factor-4E (eIF-4E) serves as the rate-limiting step for

regulation of mRNAs which contain a high degree of secondary structure, as MMP-2 does
(32;33). Our studies provide evidence that phosphorylation of the protein which regulates eIF4E activity; 4E-binding protein-1 (4EBP-1) was diminished following VP-16 exposure.
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Inefficient translation of protein is correlated with disrupted phosphorylation of 4EBP-1 (34;35).
In addition, we found that the phosphorylation and subsequent activity of P70S6K and S6
ribosomal proteins were diminished in stromal cells exposed to VP-16. Both P70S6K and S6
regulate that translation of mRNAs that contain a 5’TOP, including MMP-2 (36;37). These data
suggest a novel role for VP-16 in the disruption of cellular translational regulatory components.
These observations highlight the possibility that other proteins involved in hematopoietic
regulation may also be translationally inhibited following chemotherapy exposure.
This study has established that chemotherapy, specifically VP-16, alters regulation of
SDF-1, MMP-2, and TGF-β proteins which directly contribute to diminished stromal cell support
of hematopoiesis. In addition we have identified the mechanisms by which chemotherapy
diminishes stromal cell SDF-1 availability, MMP-2 protein expression, and increased TGF-β
activation.

These results identify specific alterations in stromal cell function while also

providing novel mechanisms by which chemotherapy disrupts stromal cell function. Finally, the
observations elucidated in this study suggest possibilities that may underlie delayed immune
reconstitution following BMT.
This work has provided some insight regarding stromal cell function following
chemotherapy, but has also led to many more unanswered questions. To determine the
contribution of MMP-2 to hematopoietic recovery following BMT, characterization of MMP-2-/mice is imperative. Initial characterization of MMP-2-/- by other investigators did not address
alterations in hematopoiesis (38). We determined that MMP-2-/- bone marrow stromal cells do
support C1.92 pro-B cells in culture, in spite of diminished chemotactic support (unpublished
observations).

Further in vivo characterization of B-cell development will be necessary to

identify any specific alterations in B-lymphopoiesis. It should also be noted that MMPs display
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overlapping functions in vivo (39), so potentially absence of MMP-2 may not impact steady-state
B-lymphopoiesis. In vitro, we found that MMP-2 has direct impact on stromal cell support of
pro-B cell chemotaxis, therefore the physiological role of MMP-2 may be to contribute to
homing and migration of transplanted cells to the bone marrow microenvironment through
regulation of chemokine gradients as well as migration of hematopoietic cells from fetal liver to
the bone marrow during fetal hematopoiesis. Development of an in vivo transplant model will aid
in identification of the contribution of MMP-2 to hematopoietic recovery following BMT.
In addition regulation of TGF-β and SDF-1, MMP-2 has also been shown to impact other
hematopoietic growth factors including IGF-1 (25).

To fully understand the consequence of

diminished MMP-2 by stromal cells chronically exposed to VP-16, it will be necessary to
evaluate the impact on additional hematopoietic factors. The bone marrow stromal cells used in
our studies predominately produce MMP-2.

However, other cells within the marrow

microenvironment express MMPs in addition to MMP-2. Bone marrow endothelial cells, a
major component of the microenvironment, produce MMP-9 (40;41). Although stromal cells do
not produce this specific MMP, extracellular surface-bound stromal proteins, like SDF-1, are
also subject to regulation by MMPs produced by endothelial cells.

Identification of the

susceptibility of other cell types and proteases, including endothelial cells and MMP-9, to
chemotherapy will further our understanding of protease mediated regulation of hematopoiesis.
One novel observation of these studies was the identification that chemotherapy alters
stromal cell regulation of MMP-2 translation.

Chapter IV summarizes evidence for the

chemotherapy-induced disruption of two cell-signaling pathways previously shown to regulate
protein translation. The observation that chemotherapy alters translational efficiency of specific
mRNAs, provides a strategy for identification of other proteins influenced by chemotherapy
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exposure. A comprehensive analysis of mRNAs which contain a 5’TOP and/or a high degree of
secondary structure has not yet been performed. Therefore, it will be important to determine if
additional proteins which influence stromal cell function display these characteristics.
VP-16 was the primary chemotherapeutic agent used in these studies, however,
incorporation of other chemotherapeutic agents yielded very similar effects on stromal cells. The
observations reported in Chapter II regarding diminished stromal cell support of pro-B cell
chemotaxis and extracellular SDF-1 following VP-16 exposure, were also consistent in stromal
cells exposed to melphalan, and 4HC (unpublished observations). Additionally, discussed in
Chapter III, TGF-β activation occurred following stromal cell exposure to VP-16, melphalan,
and 4HC. These data indicated that chemotherapy-induced disruption of stromal cell function by
a variety of agents used clinically may alter the bone marrow microenvironment. It should also
be noted that while exposure of stromal cells to these agents all resulted in diminished stromal
cell MMP-2 expression, the mechanism by which they disrupt MMP-2 expression is not uniform.
VP-16 and melphalan disrupt the regulation of proteins which control the translational efficiency
of MMP-2, while stromal cells exposed 4HC did not display alterations in phosphorylation of
4EBP-1 or P70S6K (unpublished observation). As such, the effects of specific drugs, or classes of
drugs, will need to be carefully evaluated.
Collectively, these data contribute to our understanding of chemotherapy-induced bone
marrow microenvironment damage.

Specifically, this work has identified mechanisms for

stromal cell SDF-1 availability, MMP-2 regulation, and TGF-β activation following
chemotherapy exposure. Our work has aided in the understanding of how the hematopoietic
microenvironment responds to stress, specifically chemotherapy exposure, and subsequently,
how this stress-induced damage impacts capacity to support immature B-lineage cells. This
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study improves our appreciation of stromal cells within the bone marrow microenvironment as a
vulnerable population to chemotherapy commonly used in the clinical setting. As such, this
work impacts how we consider the broad process of hematopoietic recovery following BMT.
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